Bionik Laboratories (BNKL) S-1/A 30 Sep 16 IPO registration (amended) Financial data

Document And Entity Information

Document And Entity Information	3 Months Ended
	Jun. 30, 2016
Document Information [Line Items]
Document Type	S1
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Entity Registrant Name	Bionik Laboratories Corp.
Entity Central Index Key	1,508,381
Entity Filer Category	Smaller Reporting Company

Condensed Consolidated Interim

Condensed Consolidated Interim Balance Sheets - USD ($)	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Current
Cash and cash equivalents	$ 2,749,953	$ 5,381,757	$ 6,617,082	$ 6,125,108	$ 209,933
Accounts receivable	120,360	0
Prepaid expenses and other receivables (Note 4)	188,430	231,733	188,217	158,419	81,130
Inventories (Note 5)	260,259	0
Due from related parties (Note 8)(a)	41,623	41,445	38,554	41,480	44,986
Short term advances	0	125,153	0	0	0
Loan receivable	0	379,908	307,459	0	0
Total Current Assets	3,360,625	6,159,996	7,151,312	6,325,007	336,049
Equipment (Note 6)	126,336	76,750	87,103	100,629	77,922
Intangible Assets and Goodwill (Note 3)	27,888,979	0
Total Assets	31,375,940	6,236,746	7,238,415	6,425,636	413,971
Current
Current portion of Lease Payable (Note 6)	4,603	0
Accounts Payable (Notes 8(b) and 13)	377,045	320,871	134,718	208,787	308,947
Accrued liabilities	848,281	515,979	57,840	332,946	155,463
Promissory Notes payable (Note 7)	221,699	0
Customer Deposits	86,487	0
Warrant Derivative Liability (Note 11)	5,527,049	5,135,990	6,067,869	8,382,648	0
Total Current Liabilities	7,065,164	5,972,840
Demand Notes payable (Note 7)	328,840	0
Lease Payable (Note 6)	18,032	0
Total Liabilities	7,412,036	5,972,840	6,260,427	8,924,381	464,410
Shareholders' Equity
Preferred Stock, par value $0.001; Authorized 10,000,000 Special Voting Preferred Stock, par value $0.001; Authorized - 1; Issued and outstanding - 1 (March 31, 2016 - 1)	0	0	0	0	0
Common Shares, par value $0.001; Authorized - 150,000,000 (March 31, 2016 - 150,000,000); Issued and outstanding - 35,052,384 and 50,000,000 Exchangeable Shares (March 31, 2016 - 22,591,292 and 50,000,000 Exchangeable Shares) (Note 9)	85,052	72,591	72,428	65,840	49,737
Shares to be issued	11,083,954	0	98,900	0	0
Additional paid in capital	26,727,501	11,801,146	11,412,399	10,081,394	4,936,456
Deficit	(13,974,752)	(11,651,980)	(10,647,888)	(12,688,128)	(5,053,982)
Accumulated other comprehensive income	42,149	42,149	42,149	42,149	17,350
Total Shareholders' Equity	23,963,904	263,906	977,988	(2,498,745)	(50,439)
Total Liabilities and Shareholders' Equity	$ 31,375,940	$ 6,236,746	$ 7,238,415	$ 6,425,636	$ 413,971

Condensed Consolidated Interim3

Condensed Consolidated Interim Balance Sheets [Parenthetical] - $ / shares	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000	1	1
Preferred Stock, Shares Issued		1	1	1
Preferred Stock, Shares Outstanding		1	1	1
Common Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Common Stock, Shares Authorized	150,000,000	150,000,000	150,000,000	150,000,000	200,000,000
Common Stock, Shares, Issued	35,052,384	22,591,292	22,428,313	15,839,563	0
Common Stock, Shares, Outstanding	35,052,384	22,591,292	22,428,313	15,839,563	0
Common Stock, Other Shares, Outstanding	50,000,000	50,000,000	50,000,000	50,000,000	49,737,096
Common Stock, Other Shares, Issued		50,000,000	50,000,000	50,000,000	49,737,096
Special Voting Preferred Stock [Member]
Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	1	1
Preferred Stock, Shares Issued	1	1
Preferred Stock, Shares Outstanding	1	1

Condensed Consolidated Interim4

Condensed Consolidated Interim Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended			9 Months Ended	12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2015	Dec. 31, 2014	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015
Sales	$ 164,191		$ 0
Cost of Sales	58,875		0
Gross Margin	105,316		0
Operating expenses
Sales and marketing	82,198		0
Research and development	417,790	$ 343,742	609,823	$ 1,101,820	$ 1,397,554	$ 1,489,483	$ 1,537,491
General and administrative	1,303,614	1,438,553	510,229	1,192,244	3,676,125	2,666,669	1,621,341
Share-based compensation expense (Notes 9(v) and 10)	219,248	158,244	1,297,558	112,573	1,495,837	1,709,230	484,210
Depreciation (Note 6)	10,163	14,387	17,002	34,036	63,454	59,479	44,448
Total operating expenses	2,033,013	1,954,926	2,434,612	2,440,673	6,632,970	5,924,861	3,687,490
Other expenses (income)
Imputed interest expense (Note 6)		0		27,677	0	0	27,677
Interest expense (Note 7)	15,234	0	9,963	6,212	2,839	3,018	6,391
Other income	(11,218)	(8,522)	(25,208)	(46,026)	(42,173)	(33,974)	(46,349)
Foreign exchange loss		(71,399)		36,211	112,771	184,125	36,211
Change in fair value of warrant derivative liability (Note 11)	391,059	(870,913)	(917,749)	0	(7,742,555)	(484,124)	6,387,473
Total other expenses (income)	395,075	(950,834)	(932,994)	24,074	(7,669,118)	(330,955)	6,411,403
Net (loss) income for the period	(2,322,772)	(1,004,092)	(1,501,618)	(2,464,747)	1,036,148	(5,593,906)	(10,098,893)
Foreign exchange translation adjustment		0		(24,390)	0	24,799	409
Net loss and comprehensive loss for the period	$ (2,322,772)	$ (1,004,092)	$ (1,501,618)	$ (2,489,137)	$ 1,036,148	$ (5,569,107)	$ (10,098,484)
Loss per share - basic and diluted (in dollars per share)	$ (0.03)		$ (0.02)
(Loss) income per share - basic (Note 14) (in dollars per share)		$ (0.01)		$ (0.05)	$ 0.01	$ (0.08)	$ (0.20)
(Loss) income per share - diluted (Note 14) (in dollars per share)		$ (0.01)		$ (0.05)	$ (0.08)	$ (0.08)	$ (0.20)
Weighted average number of shares outstanding - basic (Note 14) (in shares)		72,455,753		48,225,034	71,554,822	67,210,266	50,226,548
Weighted average number of shares outstanding - diluted (Note 14) (in shares)		72,455,753		48,225,034	79,984,257	67,210,266	50,226,548
Weighted average number of shares outstanding - basic and diluted	82,050,549		68,765,736

Condensed Consolidated Interim5

Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Deficiency) - USD ($)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Shares To Be Issued [Member]	Deficit [Member]	Accumulated Other Comprehensive Income [Member]
Opening Balance at Mar. 31, 2014	$ (774,626)	$ 0	$ 36,622	$ 1,736,247	$ 0	$ (2,589,235)	$ 41,740
Opening Balance (in shares) at Mar. 31, 2014		0	36,621,885
Issuance of common shares for cash	2,616,062	$ 0	$ 10,792	2,605,270	0	0	0
Issuance of common shares for cash (in shares)		0	10,792,335
Share issue costs	(11,609)	$ 0	$ 0	(11,609)	0	0	0
Shares issues on conversion of loans	239,746	$ 0	$ 1,012	238,734	0	0	0
Shares issues on conversion of loans (in shares)		0	1,012,142
Beneficial conversion feature	27,677	$ 0	$ 0	27,677	0	0	0
Shares issued on exercise of stock options	228,875	$ 0	$ 1,311	227,564	0	0	0
Shares issued on exercise of stock options (in shares)		0	1,310,734
Share compensation expense	112,573	$ 0	$ 0	112,573	0	0	0
Share compensation expense (in shares)		0	0
Net Income loss for the year/period	(2,464,747)	$ 0	$ 0	0	0	(2,464,747)	0
Foreign currency translation	(24,390)	$ 0	$ 0	0	0	0	(24,390)
Closing Balance (in shares) at Dec. 31, 2014		0	49,737,096
Closing Balance at Dec. 31, 2014	(50,439)	$ 0	$ 49,737	4,936,456	0	(5,053,982)	17,350
Opening Balance at Mar. 31, 2014	(774,626)	$ 0	$ 36,622	1,736,247	0	(2,589,235)	41,740
Opening Balance (in shares) at Mar. 31, 2014		0	36,621,885
Net Income loss for the year/period	(10,098,893)
Foreign currency translation	409
Closing Balance (in shares) at Mar. 31, 2015		1	65,839,563
Closing Balance at Mar. 31, 2015	(2,498,745)	$ 0	$ 65,840	10,081,394	0	(12,688,128)	42,149
Opening Balance at Dec. 31, 2014	(50,439)	$ 0	$ 49,737	4,936,456	0	(5,053,982)	17,350
Opening Balance (in shares) at Dec. 31, 2014		0	49,737,096
Effect of the Reverse Acquisition	0	$ 0	$ 6,000	(6,000)	0	0	0
Effect of the Reverse Acquisition (in shares)		1	6,000,063
Shares issued on private placement	4,789,404	$ 0	$ 9,840	4,779,564	0	0	0
Shares issued on private placement (in shares)		0	9,839,500
Share compensation expense	371,637	$ 0	$ 263	371,374	0	0	0
Share compensation expense (in shares)		0	262,904
Net Income loss for the year/period	(7,634,146)	$ 0	$ 0	0	0	(7,634,146)	0
Foreign currency translation	24,799	$ 0	$ 0	0	0	0	24,799
Closing Balance (in shares) at Mar. 31, 2015		1	65,839,563
Closing Balance at Mar. 31, 2015	(2,498,745)	$ 0	$ 65,840	10,081,394	0	(12,688,128)	42,149
Opening Balance at Dec. 31, 2014	(50,439)	$ 0	$ 49,737	4,936,456	0	(5,053,982)	17,350
Opening Balance (in shares) at Dec. 31, 2014		0	49,737,096
Net Income loss for the year/period	(5,593,906)
Foreign currency translation	24,799
Closing Balance (in shares) at Dec. 31, 2015		1	72,428,313
Closing Balance at Dec. 31, 2015	977,988	$ 0	$ 72,428	11,412,399	98,900	(10,647,888)	42,149
Opening Balance at Mar. 31, 2015	(2,498,745)	$ 0	$ 65,840	10,081,394	0	(12,688,128)	42,149
Opening Balance (in shares) at Mar. 31, 2015		1	65,839,563
Shares issued on private placement	0	$ 0	$ 6,568	(6,568)	$ 0	0	0
Shares issued on private placement (in shares)		0	6,568,750		0
Share compensation expense	1,297,558	$ 0	$ 0	1,297,558	$ 0	0	0
Share compensation expense (in shares)		0	0		0
Net Income loss for the year/period	(1,501,618)	$ 0	$ 0	0	$ 0	(1,501,618)	0
Closing Balance (in shares) at Jun. 30, 2015		1	72,408,313		0
Closing Balance at Jun. 30, 2015	(2,702,805)	$ 0	$ 72,408	11,372,384	$ 0	(14,189,746)	42,149
Opening Balance at Mar. 31, 2015	(2,498,745)	$ 0	$ 65,840	10,081,394	0	(12,688,128)	42,149
Opening Balance (in shares) at Mar. 31, 2015		1	65,839,563
Shares issued on private placement	0	$ 0	$ 6,568	(6,568)	0	0	0
Shares issued on private placement (in shares)		0	6,568,750
Shares issued for services	98,900	$ 0	$ 0	0	98,900	0	0
Shares issued for services (in shares)		0	0
Share compensation expense	1,337,593	$ 0	$ 20	1,337,573	0	0	0
Share compensation expense (in shares)		0	20,000
Net Income loss for the year/period	2,040,240	$ 0	$ 0	0	0	2,040,240	0
Foreign currency translation	0	$ 0	$ 0	0	0	0	0
Closing Balance (in shares) at Dec. 31, 2015		1	72,428,313
Closing Balance at Dec. 31, 2015	977,988	$ 0	$ 72,428	11,412,399	98,900	(10,647,888)	42,149
Opening Balance at Mar. 31, 2015	(2,498,745)	$ 0	$ 65,840	10,081,394	0	(12,688,128)	42,149
Opening Balance (in shares) at Mar. 31, 2015		1	65,839,563
Net Income loss for the year/period	1,036,148
Foreign currency translation	0
Closing Balance (in shares) at Mar. 31, 2016		1	72,591,292
Closing Balance at Mar. 31, 2016	263,906	$ 0	$ 72,591	11,801,146	0	(11,651,980)	42,149
Opening Balance at Jun. 30, 2015	(2,702,805)	$ 0	$ 72,408	11,372,384	$ 0	(14,189,746)	42,149
Opening Balance (in shares) at Jun. 30, 2015		1	72,408,313		0
Shares issued for services	169,700	$ 0	$ 117	169,583	$ 0	0	0
Shares issued for services (in shares)		0	117,471		0
Cashless exercise of warrants	60,966	$ 0	$ 46	60,920	$ 0	0	0
Cashless exercise of warrants (in shares)		0	45,508		0
Share compensation expense	198,279	$ 0	$ 20	198,259	$ 0	0	0
Share compensation expense (in shares)		0	20,000		0
Net Income loss for the year/period	2,537,766	$ 0	$ 0	0	$ 0	2,537,766	0
Closing Balance (in shares) at Mar. 31, 2016		1	72,591,292
Closing Balance at Mar. 31, 2016	263,906	$ 0	$ 72,591	11,801,146	0	(11,651,980)	42,149
Opening Balance at Dec. 31, 2015	977,988	$ 0	$ 72,428	11,412,399	98,900	(10,647,888)	42,149
Opening Balance (in shares) at Dec. 31, 2015		1	72,428,313
Shares issued for services	70,800	$ 0	$ 117	169,583	(98,900)	0	0
Shares issued for services (in shares)		0	117,471
Cashless exercise of warrants	60,966	$ 0	$ 46	60,920	0	0	0
Cashless exercise of warrants (in shares)		0	45,508
Share compensation expense	158,244	$ 0	$ 0	158,244	0	0	0
Share compensation expense (in shares)		0	0
Net Income loss for the year/period	(1,004,092)	$ 0	$ 0	0	0	(1,004,092)	0
Foreign currency translation	0	$ 0	$ 0	0	0	0	0
Closing Balance (in shares) at Mar. 31, 2016		1	72,591,292
Closing Balance at Mar. 31, 2016	263,906	$ 0	$ 72,591	11,801,146	0	(11,651,980)	42,149
Shares issued on Acquisition (Note 3)	23,177,000	$ 0	$ 12,340	12,080,706	$ 11,083,954	0	0
Shares issued on Acquisition (Note 3) (in shares)		0	12,339,843		11,310,157
Shares issued for services	59,500	$ 0	$ 70	59,430	$ 0	0	0
Shares issued for services (in shares)		0	70,000		0
Stock compensation expense - vested options on Acquisition (Note 3)	2,582,890	$ 0	$ 0	2,582,890	$ 0	0	0
Cashless exercise of warrants	$ 43,562	$ 0	$ 51	43,511	$ 0	0	0
Cashless exercise of warrants (in shares)	51,249	0	51,249		0
Share compensation expense	$ 159,818	$ 0	$ 0	159,818	$ 0	0	0
Share compensation expense (in shares)		0	0		0
Net Income loss for the year/period	(2,322,772)	$ 0	$ 0	0	$ 0	(2,322,772)	0
Closing Balance (in shares) at Jun. 30, 2016		1	85,052,384		11,310,157
Closing Balance at Jun. 30, 2016	$ 23,963,904	$ 0	$ 85,052	$ 26,727,501	$ 11,083,954	$ (13,974,752)	$ 42,149

Condensed Consolidated Interim6

Condensed Consolidated Interim Statements of Cash Flows - USD ($)	3 Months Ended			9 Months Ended	12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2015	Dec. 31, 2014	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015
Operating activities
Net loss for the period	$ (2,322,772)	$ (1,004,092)	$ (1,501,618)	$ (2,464,747)	$ 1,036,148	$ (5,593,906)	$ (10,098,893)
Adjustment for items not affecting cash
Depreciation	10,163	14,387	17,002	34,036	63,454	59,479	44,448
Imputed interest		0		27,677	0	0	27,677
Interest expense	15,234	(4,701)	0	0	7,697	(7,459)	179
Share based compensation expense	159,818	158,244	1,297,558	112,573	1,495,837	1,709,230	273,887
Shares issued for services	59,500	70,800	0	0	169,700	0	210,323
Shares to be issued for services		0		0	0	98,900	0
Change in fair value of warrant derivative liability	391,059	(870,913)	(917,749)	0	(7,742,555)	(484,124)	6,387,473
Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities	(1,686,998)	(1,636,275)	(1,104,807)	(2,290,461)	(4,969,719)	(4,217,880)	(3,154,906)
Changes in non-cash working capital items
Accounts receivable	(113,870)		0
Prepaid expenses and other receivables	60,142	(43,516)	(5,934)	420,709	(73,314)	(107,087)	337,451
Due from related parties	(178)	(2,891)	(671)	0	35	6,432	0
Inventories	(71,380)		0
Accounts payable	(703,526)	186,153	(11,705)	195,427	112,129	(174,229)	123,654
Accrued liabilities	(382,629)	458,139	(299,676)	34,847	183,033	(97,623)	228,840
Net cash used in operating activities	(2,898,439)	(1,038,390)	(1,422,793)	(1,639,478)	(4,747,836)	(4,590,387)	(2,464,961)
Investing activities
Acquisition of equipment	0	(3,032)	(30,917)	(109,316)	(42,863)	(80,195)	(148,136)
Advances		(125,153)		0	(125,153)	0	0
Provision of a loan receivable	0	(68,750)	(150,000)	0	(379,908)	(300,000)	0
Net cash used in investing activities	0	(196,935)	(180,917)	(109,316)	(547,924)	(380,195)	(148,136)
Financing activities
Proceeds from issuance of shares, net of issue costs	0	0	4,552,409	2,604,453	4,552,409	11,341,397	9,393,441
Repayment of proceeds from loans payable		0		(733,293)	0	0	(733,293)
Proceeds from the exercise of options		0		228,875	0	0	228,875
Repayment of loans from related parties		0		(111,357)	0	0	(111,357)
Cash acquired on acquisition	266,635		0
Net cash provided by financing activities	266,635	0	4,552,409	1,988,678	4,552,409	11,341,397	8,777,666
Effects of foreign currency exchange rate changes	0	0	4,409	(33,433)	0	36,334	(42,943)
Net (decrease) increase in cash and cash equivalents for the period	(2,631,804)	(1,235,325)	2,953,108	206,451	(743,351)	6,407,149	6,121,626
Cash and cash equivalents, beginning of period	5,381,757	6,617,082	6,125,108	3,482	6,125,108	209,933	3,482
Cash and cash equivalents, end of period	2,749,953	5,381,757	$ 9,078,216	209,933	5,381,757	6,617,082	6,125,108
Supplemental information:
Issuance of shares on conversion of loans		$ 0		$ 239,746	$ 0	$ 500,000	$ 500,000
Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]
Current assets, including cash acquired of $266,635	478,843
Equipment	59,749
Intangible assets and goodwill	27,888,979
Accounts payable	(241,299)
Accrued liabilities	(361,029)
Customer deposits	(86,487)
Demand notes payable	(324,894)
Promissory notes payable	(217,808)
Bionik advance	(1,436,164)
Non-cash consideration	$ 25,759,890

Condensed Consolidated Interim7

Condensed Consolidated Interim Statements of Cash [Parenthetical] - USD ($)	3 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash Acquired from Acquisition	$ 266,635	$ 0

NATURE OF OPERATIONS

NATURE OF OPERATIONS	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	1. NATURE OF OPERATIONS The Company and its Operations Bionik Laboratories Corp. (formerly Drywave Technologies Inc., the “Company” or “Bionik”) was incorporated on January 8, 2010 in the State of Colorado as Strategic Dental Management Corp. On July 16, 2013, the Company changed its name to Drywave Technologies Inc. (“Drywave”) and its state of incorporation from Colorado to Delaware. Effective February 13, 2015, the Company changed its name to Bionik Laboratories Corp. and reduced the authorized number of shares of common stock from 200,000,000 150,000,000 On February 26, 2015, the Company entered into a Share Exchange Agreement and related transactions whereby it acquired Bionik Laboratories Inc., a Canadian Corporation (Bionik Canada and Bionik Canada issued 50,000,000 Exchangeable Shares, representing a 3.14 exchange ratio, for 100% of the then outstanding common shares of Bionik Canada (the “Merger”). The Exchangeable Shares are exchangeable at the option of the holder, each into one share of the common stock of the Company. In addition the Company issued one Special Preferred Voting Share (the “Special Preferred Share”) (Note 9). As a result of the shareholders of Bionik Canada having a controlling interest in the Company subsequent to the Merger, for accounting purposes the Merger does not constitute a business combination. The transaction has been accounted for as a recapitalization of the Company with Bionik Canada being the accounting acquirer even though the legal acquirer is Bionik, accordingly, the historic financial statements of Bionik Canada are presented as the comparative balances for the period prior to the Merger. References to the Company refer to the Company and its wholly-owned subsidiaries, Bionik Acquisition Inc. and Bionik Canada. References to Drywave relate to the Company prior to the Merger. On April 21, 2016, the Company acquired all of the outstanding shares and, accordingly, all assets and liabilities of Interactive Motion Technologies, Inc. (IMT), a Boston, Massachusetts-based global pioneer and leader in providing effective robotic products for neurorehabilitation, pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) dated March 1, 2016, with IMT, Hermano Igo Krebs, and Bionik Mergerco Inc., a Massachusetts corporation and our wholly owned subsidiary (Bionik Mergeco). The merger agreement provided for the merger of Bionik Mergerco with and into IMT, with IMT surviving the merger as the Company’s wholly-owned subsidiary. In return for acquiring IMT, IMT shareholders received or will receive up to an aggregate of 23,650,000 The Company is a global pioneering robotics company focused on providing rehabilitation solutions to individuals with neurological disorders, specializing in designing, developing and commercializing cost-effective physical rehabilitation technologies, prosthetics, and assisted robotic products. The Company strives to innovate and build devices that can rehabilitate and improve an individual’s health, comfort, accessibility and quality of life through the use of advanced algorithms and sensing technologies that anticipate a user’s every move. The unaudited condensed consolidated interim financial statements consolidate the Company and its wholly-owned subsidiaries Bionik Canada, Bionik Acquisition Inc. and Bionik, Inc. (the former IMT) since its acquisition on April 21, 2016. These unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"), which contemplates continuation of the Company as a going concern, which assumes the realization of assets and satisfaction of liabilities and commitments in the normal course of business. As at June 30, 2016, the Company had a working capital deficit of $ 3,704,539 23,963,904 2,322,772 The Company’s principal offices are located at 483 Bay Street, N105, Toronto, Ontario, Canada M5G 2C9 and Bionik, Inc.’s address is 80 Coolidge Hill Road, Watertown, MA. USA 02472. Liquidity Largely as a result of significant research and development activities related to the development of the Company’s advanced technology and commercialization of this technology into its medical device business, the Company has incurred significant operating losses and negative cash flows from operations since inception. As of June 30, 2016, the Company had an accumulated deficit of $ 13,974,752 Cash on hand at June 30, 2016 was $ 2,749,953 931,103 The Company’s actual capital requirements may vary significantly and will depend on many factors. Consequently, the Company will require significant additional financing in the immediate future, which the Company intends to raise before December 31, 2016 through corporate collaborations, public or private equity offerings, debt financings or warrant solicitations. Sales of additional equity securities by the Company could result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required in sufficient amounts, on acceptable terms or at all. In the event that the necessary additional financing is not obtained, the Company would reduce its discretionary overhead costs substantially, including research and development, general and administrative, and sales and marketing expenses or otherwise curtail operations. However, the Company expects the foregoing, or a combination thereof, to meet the Company’s anticipated cash requirements for the next 12 months.	NATURE OF OPERATIONS The Company and its Operations Bionik Laboratories Corp. (formerly Drywave Technologies Inc., the “Company” or “Bionik”) was incorporated on January 8, 2010 in the State of Colorado as Strategic Dental Management Corp. On July 16, 2013, the Company changed its name to Drywave Technologies Inc. (“Drywave”) and its state of incorporation from Colorado to Delaware. Effective February 13, 2015, the Company changed its name to Bionik Laboratories Corp. and reduced the authorized number of shares of common stock from 200,000,000 150,000,000 The Company is a bioengineering research and development company targeting diseases and injuries that impact human mobility. The Company is working towards its first product, which will be the “ARKE”, a robotic pair of exoskeleton legs to be used for rehabilitation purposes. These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), which contemplates continuation of the Company as a going concern, which assumes the realization of assets and satisfaction of liabilities and commitments in the normal course of business. On February 26, 2015, the Company finalized a Share Exchange Agreement whereby Bionik Canada issued 50,000,000 3.14 100 As a result of the shareholders of Bionik Canada having a controlling interest in the Company subsequent to the Merger, for accounting purposes the Merger does not constitute a business combination. The transaction has been accounted for as a recapitalization of the Company with Bionik Canada being the accounting acquirer even though the legal acquirer is Bionik, accordingly, the historic financial statements of Bionik Canada are presented as the comparative balances for the period prior to the Merger. References to the Company refer to the Company and its subsidiaries, Bionik Acquisition Inc. and Bionik Laboratories Inc. References to Drywave relate to the Company prior to the Merger. The Company has not yet realized any revenues from its planned operations. As at March 31, 2016, the Company had working capital of $ 187,156 890,885 263,906 2,498,745 977,988 50,439 1,004,092 1,036,148 5,569,107 2,489,137

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. SIGNIFICANT ACCOUNTING POLICIES These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements and should be read in conjunction with those annual audited financial statements filed on Form 10-KT for the period ended March 31, 2016. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect adjustments, necessary to present fairly the Company's financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2017. Early adoption is not permitted. The impact on the consolidated financial statements of adopting ASU 2014-09 will be assessed by management. In August 2014, the FASB issued a new financial accounting standard on going concern, ASU No. 2014-15, “Presentation of Financial Statements – Going Concern (Sub-Topic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The standard provides guidance about management’s responsibility to evaluate whether there is a substantial doubt about the organization’s ability to continue as a going concern. The amendments in this Update apply to all companies. They become effective in the annual period ending after December 15, 2016, with early application permitted. The impact on the consolidated financial statements of adopting ASU 2014-15 will be assessed by management. In September 2015, the FASB issued ASU No. 2015-16, “Simplifying the Accounting for Measurement-Period Adjustments,” which illustrates certain guidance governing adjustments to the provisional amounts recognized at the acquisition date with a corresponding adjustment to goodwill. Such adjustments are required when new information is obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement amounts initially recognized or would have resulted in the recognition of additional assets and liabilities. ASU No. 2015-16 eliminates the requirement to retrospectively account for such adjustments. ASU No. 2015-16 is effective for the fiscal year commencing after December 15, 2016. The Company has adopted this ASU No. 2015-16 as at and for the three and twelve month periods ended March 31, 2016. There was no material effect on the consolidated financial position or the consolidated results of operations and comprehensive loss. In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes,” which requires that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015-17 is effective for the fiscal year commencing after December 15, 2017. The Company does not anticipate that the adoption of ASU No. 2015-17 will have a material effect on the consolidated financial position or the consolidated results of operations. In February 2016, the FASB issued ASU 2016-02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASI 2016-02 will have on the consolidated financial position and the consolidated results of operations. In March 2016, the FASB issued ASU 2016-09, "Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting". Several aspects of the accounting for share-based payment award transaction are simplified, including (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company is still assessing the impact that the adoption of ASI 2016-09 will have on the consolidated financial position and the consolidated results of operations. The Company recognizes revenue upon completion of its products when they are shipped from its place of manufacture. The Company’s derivative warrant instruments are measured at fair value using a simulation model which takes into account, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock, its expected volatility, holding cost and the risk-free interest rate for the term of the warrant (Note 11). The warrant derivative liability is revalued at each reporting period and changes in fair value are recognized in the condensed consolidated interim statements of operations and comprehensive loss under the caption “Change in fair value of warrant derivative liability”. The selection of the appropriate valuation model and the inputs and assumptions that are required to determine the valuation requires significant judgment and requires management to make estimates and assumptions that affect the reported amount of the related liability and reported amounts of the change in fair value. Actual results could differ from those estimates, and changes in these estimates are recorded when known. As the derivative warrant liability is required to be measured at fair value at each reporting date it is reasonably possible that these estimates and assumptions could change in the near term. The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the balance sheet and amount to $ 61,380 15,190 On April 1, 2015, Bionik Canada and Bionik Acquisition Inc. changed its functional currency from the Canadian Dollar to the U.S. Dollar. This reflects the fact that the majority of the Company’s business is influenced by an economic environment denominated in U.S. currency as well the Company anticipates revenues to be earned in U.S. dollars. The change in accounting treatment is applied prospectively. The functional currency is separately determined for the Company and each of its subsidiaries, and is used to measure the financial position and operating results. The functional currency of the Company and its wholly-owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction. ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs which are as observable as possible and the methods most applicable to the specific situation of each company or valued item. The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, other receivables, accounts payable and accrued liabilities, due from related parties approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. As at June 30, 2016, the Company’s warrant derivative liability was measured at fair value at each reporting period using a simulation model based on Level 3 inputs. The Company’s policy is to recognize transfers into and out of Level 3 as of the date of the event or change in the circumstances that caused the transfer. There were no such transfers during the period.	SIGNIFICANT ACCOUNTING POLICIES The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and changes in these estimates are recorded when known. Significant estimates made by management include: the valuation of the warrant derivative liability and the valuation allowance for deferred tax assets. The selection of the appropriate valuation model to apply to the warrant derivative liability and the related inputs and assumptions that are required to determine that valuation require significant judgment and require management to make estimates and assumptions that affect the reported amount of the related liability and reported amounts of the change in fair value. As the derivative warrant liability is required to be measured at fair value at each reporting date it is reasonably possible that these estimates and assumptions could change in the near term. On April 1, 2015, Bionik Canada and Bionik Acquisition Inc. changed its functional currency from the Canadian Dollar to the U.S. Dollar. This reflects the fact that the majority of the Company’s business is influenced by an economic environment denominated in U.S. currency as well the Company anticipates revenues to be earned in U.S. dollars. The change in accounting treatment was applied prospectively. The functional currency is separately determined for the Company and each of its subsidiaries, and is used to measure the financial position and operating results. The functional currency of the Company and its wholly-owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction. Property and equipment are recorded at cost. Depreciation is computed using the declining balance method, over the estimated useful lives of these assets. The costs of improvements that extend the life of equipment are capitalized. All ordinary repair and maintenance costs are expensed as incurred. Property and equipment are depreciated as follows: Computer & Electronics 50 Furniture and Fixtures 20 Tools and Parts 20 The Company has yet to recognize any revenue. The Company intends to record revenue when it is realized, or realizable and earned. The Company will consider revenue to be realized, or realizable and earned, when the following revenue recognition requirements are met: persuasive evidence of an arrangement exists; the products or services have been accepted by the customer via delivery or acceptance; the sales price is fixed or determinable; and collectability is reasonably assured. The Company receives certain grant and input tax credit recoveries from the Canadian government in compensation for eligible expenditures. These are presented as other income in the statement of operations and comprehensive loss as they generally relate to a number of the Company’s operating expenses, such as salaries and benefits, research and development and professional and consulting fees. The recoveries are recognized in the corresponding period when such expenses are incurred and collection of the grant funds is assured. Cash and cash equivalents include highly liquid investments with original terms to maturity of 90 days or less at the date of purchase. For all periods presented cash and cash equivalents consisted entirely of cash. The Company is engaged in research and development work. Research and development costs are charged as operating expense of the Company as incurred. The Company’s derivative warrant instruments are measured at fair value using a simulation model which takes into account, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock, its expected volatility, holding cost and the risk-free interest rate for the term of the warrant (Note 10). The warrant derivative liability is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss under the caption “Change in fair value of warrant derivative liability”. ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for the way that public business enterprises report information about operating segments in the Company’s consolidated financial statements. Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company does not have any reportable segments. All of its operations and assets are domiciled in Canada. Income taxes are computed in accordance with the provisions of ASC Topic 740, which requires, among other things, a liability approach to calculating deferred income taxes. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized in its consolidated financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The Company is required to make certain estimates and judgments about the application of tax law, the expected resolution of uncertain tax positions and other matters. In the event that uncertain tax positions are resolved for amounts different than the Company’s estimates, or the related statutes of limitations expire without the assessment of additional income taxes, the Company will be required to adjust the amounts of related assets and liabilities in the period in which such events occur. Such adjustment may have a material impact on Bionik’s income tax provision and results of operations. ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs which are as observable as possible and the methods most applicable to the specific situation of each company or valued item. The carrying amounts reported in the balance sheets for cash and cash equivalents, other receivables, accounts payable, accrued liabilities, and due from related parties’ approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. As at March 31, 2016, the Company’s warrant derivative liability is measured at fair value at each reporting period using a simulation model based on Level 3 inputs. The Company’s policy is to recognize transfers into and out of Level 3 as of the date of the event or change in the circumstances that caused the transfer. There were no such transfers during the year. Basic and diluted loss per share has been determined by dividing the net loss available to shareholders for the applicable period by the basic and diluted weighted average number of shares outstanding, respectively. The diluted weighted average number of shares outstanding is calculated as if all dilutive options had been exercised or vested at the later of the beginning of the reporting period or date of grant, using the treasury stock method. Loss per common share is computed by dividing the net loss by the weighted average number of shares of common shares outstanding during the period. Common share equivalents, options and warrants are excluded from the computation of diluted loss per share when their effect is anti-dilutive. The Company follows the ASC Topic 360, which requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable. In performing the review for recoverability, if future undiscounted cash flows (excluding interest charges) from the use and ultimate disposition of the assets are less than their carrying values, an impairment loss represented by the difference between its fair value and carrying value, is recognized. When properties are classified as held for sale they are recorded at the lower of the carrying amount or the expected sales price less costs to sell. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2017. Early adoption is not permitted. The impact on the consolidated financial statements of adopting ASU 2014-09 will be assessed by management. In August 2014, the FASB issued a new financial accounting standard on going concern, ASU No. 2014-15, “Presentation of Financial Statements – Going Concern (Sub-Topic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The standard provides guidance about management’s responsibility to evaluate whether there is a substantial doubt about the organization’s ability to continue as a going concern. The amendments in this Update apply to all companies. They become effective in the annual period ending after December 15, 2016, with early application permitted. The impact on the consolidated financial statements of adopting ASU 2014-15 will be assessed by management. In March 2016, the FASB issued ASU 2016-09, "Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting". Several aspects of the accounting for share-based payment award transaction are simplified, including (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company is still assessing the impact that the adoption of ASI 2016-09 will have on the consolidated financial position and the consolidated results of operations. In February 2016, the FASB issued ASU 2016-02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASI 2016-02 will have on the consolidated financial position and the consolidated results of operations. In September 2015, the FASB issued ASU No. 2015-16, “Simplifying the Accounting for Measurement-Period Adjustments,” which illustrates certain guidance governing adjustments to the provisional amounts recognized at the acquisition date with a corresponding adjustment to goodwill. Such adjustments are required when new information is obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement amounts initially recognized or would have resulted in the recognition of additional assets and liabilities. ASU No. 2015-16 eliminates the requirement to retrospectively account for such adjustments. ASU No. 2015-16 is effective for the fiscal year commencing on January 1, 2016. The Company has adopted this ASU No. 2015-16 as at and for the three and twelve month periods ended March 31, 2016. There was no material effect on the consolidated financial position or the consolidated results of operations and comprehensive loss.

ACQUISITION

ACQUISITION	3 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	3. ACQUISITION On April 21, 2016 100 Subject to the indemnification and escrow arrangements described in the Merger Agreement, Bionik has issued (or has reserved for issuance) an aggregate of 23,650,000 12,339,843 23,650,000 11,310,157 Bionik also assumed each of the 3,895,000 3,000,000 1,000,000 0.25 1,000,000 0.95 1,000,000 1.05 2,582,890 The Company acquired the assets of IMT, which also included five licensed patents, a MIT Licence Agreement, three FDA listed products, a FDA inspected manufacturing facility, extensive clinical and sales data, a sales group and international distributors. Due to the complexities in identifying and valuing the intangible assets acquired, the Company has not yet finalized the purchase price allocation. At this time the Company is not practicably able to estimate the fair value of each identifiable asset. The Company has retained an independent valuator to determine the purchase price allocation. At this time the Company anticipates the intangible assets to consist of clinical data, sales data, license and patents/technology acquired and any excess to result in goodwill. As at April 21, 2016 $ Consideration Paid: Fair value of 23,650,000 common shares (a) 23,177,000 Fair value of vested stock options (b) 2,582,890 25,759,890 Allocation of purchase price: Assets Acquired: Cash and cash equivalents 266,635 Accounts receivable 6,490 Inventories 188,879 Prepaid expenses and other current assets 16,839 Equipment 59,749 Liabilities assumed: Accounts payable (241,299) Accrued liabilities (361,029) Customer deposits (86,487) Demand notes payable (324,894) Promissory notes payable (217,808) Bionik advance (1,436,164) Net assets acquired (2,129,089) Intangible assets and goodwill 27,888,979 25,759,890 (a) The fair value of common shares is based on $ 0.98 (b) The fair value of the vested stock options was determined using the Black Scholes option pricing model with the following key assumptions: a risk free rate of 1.59 0 114 For the period April 21 - June 30, 2016 (unaudited) Revenue $ 162,588 Net loss and comprehensive loss $ (292,634) Pro forma results of operations Three Months Ended June 30, 2016 2015 (unaudited) Revenue $ 166,028 $ 438,414 Net loss and comprehensive loss $ (407,245) $ (124,548) *There were no material or nonrecurring adjustments in the supplemental pro forma revenue or results of operations as shown above.

PREPAID EXPENSES AND OTHER RECE

PREPAID EXPENSES AND OTHER RECEIVABLES	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expense And Other Receivables [Text Block]	4. PREPAID EXPENSES AND OTHER RECEIVABLES June 30, March 31, $ $ Prepaid expenses and sundry receivables 75,831 87,979 Prepaid insurance 83,329 107,259 Sales taxes receivable (i) 29,270 36,495 188,430 231,733 (i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.	3. PREPAID EXPENSES AND OTHER RECEIVABLES March 31, March 31, December 31, December 31, $ $ $ $ Prepaid expenses and other receivables 87,979 6,242 120,661 18,172 Prepaid insurance 107,259 126,771 12,966 40,630 Sales taxes receivable (i) 36,495 25,406 54,590 22,328 231,733 158,419 188,217 81,130 i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

LOANS RECEIVABLE AND SHORT TERM

LOANS RECEIVABLE AND SHORT TERM ADVANCES	3 Months Ended
	Mar. 31, 2016
Receivables [Abstract]
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	4. LOANS RECEIVABLE AND SHORT TERM ADVANCES During the year ended December 31, 2015, the Company provided two loans to Interactive Motion Technologies Inc. (IMT) which the Company has subsequently acquired (the “Acquisition”) (Note 16) on April 21, 2016. The original loans were an aggregate amount of $ 300,000 6 200,000 68,750 11,158 7,459 379,908 125,153

INVENTORIES

INVENTORIES	3 Months Ended
	Jun. 30, 2016
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	5. INVENTORIES June 30, March 31, $ $ Raw Materials 218,047 - Work in Progress 42,212 - 260,259 -

EQUIPMENT

EQUIPMENT	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	6. EQUIPMENT June 30, 2016 March 31, 2016 Cost Accumulated Net Cost Accumulated Net $ $ $ $ $ $ Computers and electronics 262,853 184,636 78,217 152,246 96,379 55,867 Furniture and fixtures 36,795 24,361 12,434 22,496 10,118 12,378 Demonstration equipment 28,800 1,200 27,600 - - - Manufacturing equipment 84,442 84,442 - - - - Tools and parts 11,422 3,337 8,085 11,422 2,917 8,505 424,312 297,976 126,336 186,164 109,414 76,750 Included in Computers and Electronics are assets under capital lease of $ 23,019 4,603 18,032 10,163 17,002	5. EQUIPMENT March 31, 2016 March 31, 2015 Cost Accumulated Net Cost Accumulated Net $ $ $ $ $ $ Computers and electronics 152,246 96,379 55,867 107,369 33,933 73,436 Furniture and fixtures 22,496 10,118 12,378 23,832 7,689 16,143 Tools and parts 11,422 2,917 8,505 12,100 1,050 11,050 186,164 109,414 76,750 143,301 42,672 100,629 Equipment consisted of the following as at December 31, 2015 and December 31, 2014: December 31, 2015 December 31, 2014 Cost Accumulated Net Cost Accumulated Net $ $ $ $ $ $ Computers and electronics 148,214 84,072 64,142 77,650 27,438 50,212 Furniture and fixtures 23,496 9,478 14,018 24,909 7,325 17,584 Tools and parts 11,422 2,479 8,943 11,913 1,787 10,126 183,132 96,029 87,103 114,472 36,550 77,922 Equipment is recorded at cost less accumulated depreciation. Depreciation expense during the three and twelve month periods ended March 31, 2016 was $ 14,387 63,454 59,479 34,036

NOTES PAYABLE

NOTES PAYABLE	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	7. NOTES PAYABLE Demand Notes payable The Company has outstanding notes payable (“Notes”) of $ 328,840 148,974 3.50 15 Interest expense incurred on the Notes totalled $ 3,325 Promissory Notes payable In February 2014, the Company borrowed $ 200,000 10 3,890 Subsequent to June 30, 2016, the Promissory Note was extended to March 2017 under the same terms and conditions stated above.	6. CONVERTIBLE SECURED PROMISSORY NOTE On December 8, 2011, the Company received $ 61,500 60,000 121,500 1 convert the principal plus accrued interest at a discount of 20% to the share price in the event of a qualifying financing The note matured on February 28, 2014, at this point the conversion option expired and the note became due on demand; however, no repayment was demanded. Upon the occurrence of the April financing (Note 8(i)) the Company agreed to honor the original conversion option and a beneficial conversion feature of $ 27,677 27,677 On May 9, 2014, the lender converted the note plus accrued interest into common shares based on the 20% discount to the $ 0.22

RELATED PARTY TRANSACTIONS AND

RELATED PARTY TRANSACTIONS AND BALANCES	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	8. RELATED PARTY TRANSACTIONS AND BALANCES Due from related parties (a) As of June 30, 2016, the Company had advances receivable from the Chief Operating Officer (“COO”) and former Chief Technology Officer (“CTO”) for $ 41,623 41,445 1 392 1,148 The Company advanced funds to settle a tax assessment; the Company paid additional salary amounts that had not been made during the period; and, the Company reimbursed $ 37,837 44,000 Accounts payable and accrued liabilities (b) As at June 30, 2016, $ 1,118 2,694 3,284 16,941 8,812 116 102	7. RELATED PARTY TRANSACTIONS AND BALANCES Due from related parties (a) As of March 31, 2016 the Company had advances receivable from the Chief Operating Officer (“COO”) and the former Chief Technology Officer (“CTO”) for $ 41,445 41,480 38,554 44,986 1 1,148 392 756 Accounts payable and accrued liabilities (b) As at March 31, 2016, $ 2,694 1,490 2,970 4,220 3,284 9,752 856 5,930 8,812 7,025 878 116 346 Issuance of shares to settle due to related party (c) During the nine months ended December 31, 2014, one advance amounting to $ 85,947 95,000 331,443

SHARE CAPITAL

SHARE CAPITAL	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	9. SHARE CAPITAL June 30, 2016 March 31, 2016 Number of $ Number of $ Exchangeable Shares: Balance beginning and end of the period 50,000,000 50,000 50,000,000 50,000 Common Shares Balance at beginning of the period 22,591,292 22,591 22,428,313 22,428 Shares issued on acquisition (Note 3) 12,339,843 12,339 Shares issued for services (v) 70,000 70 117,471 117 Cashless exercise of warrants (iv) 51,249 51 45,508 46 Balance at end of the period 35,052,384 35,051 22,591,292 22,591 TOTAL COMMON SHARES 85,052,384 85,052 72,591,292 72,591 (i) On April 21, 2015, the Company issued 3,115,000 2,492,000 Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years 311,500 0.80 435,682 (ii) On May 27, 2015, the Company issued 1,418,750 1,135,000 Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years 147,566 141,875 0.80 4 37,739 (iii) On June 30, 2015, the Company issued 2,035,000 1,628,000 Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years 211,656 203,500 0.80 4 74,625 (iv) During the three month period ended June 30, 2016, 51,249 262,045 0.80 43,562 (v) The Company issued 70,000 59,500 Special Voting Preferred Share In connection with the Merger (Note 1), on February 26, 2015, the Company entered into a voting and exchange trust agreement (the “Trust Agreement”). Pursuant to the Trust Agreement, the Company issued one Special Voting Preferred Share to the Trustee, and the parties created a trust for the Trustee to hold the Special Voting Preferred Share for the benefit of the holders of the Exchangeable Shares (the “Beneficiaries”). Pursuant to the Trust Agreement, the Beneficiaries will have voting rights in the Company equivalent to what they would have had they received shares of common stock in the same amount as the Exchangeable Shares held by the Beneficiaries. In connection with the Merger and the Trust Agreement, effective February 20, 2015, the Company filed a certificate of designation of the Special Voting Preferred Share (the “Special Voting Certificate of Designation”) with the Delaware Secretary of State. Pursuant to the Special Voting Certificate of Designation, one share of the Company’s blank check preferred stock was designated as Special Voting Preferred Share. The Special Voting Preferred Share entitles the Trustee to exercise the number of votes equal to the number of Exchangeable Shares outstanding on a one-for-one basis during the term of the Trust Agreement. The Special Voting Preferred Share is not entitled to receive any dividends or to receive any assets of the Company upon liquidation, and is not convertible into common shares of the Company. The voting rights of the Special Voting Preferred Share will terminate pursuant to and in accordance with the Trust Agreement. The Special Voting Preferred Share will be automatically cancelled at such time as no Exchangeable Shares are held by a Beneficiary.	8. SHARE CAPITAL March 31, 2016 December 31, 2015 Number of Number of shares $ shares $ Exchangeable Shares: Balance, beginning of period 50,00,000 50,000 50,000,000 50,000 Balance, end of the year 50,000,000 50,000 50,000,000 50,000 Common Shares: Balance, beginning of the period 22,428,313 22,428 15,839,563 15,840 Shares issued under private placement - - (x)-(xii) 6,568,750 6,568 Shares issued for services (xiii) 117,471 117 (xiii) 20,000 20 Cashless exercise of warrants (xiv) 45,508 46 - - Balance, end of the period 22,591,292 22,591 22,428,313 22,428 TOTAL COMMON SHARES 72,591,292 72,591 72,428,313 72,428 March 31, 2015 December 31, 2014 Number of Number of shares $ shares $ Exchangeable Shares: Balance at beginning of period 49,737,096 49,737 36,621,885 36,622 Shares issued for services (v) 262,904 263 - - Shares issued under private placement (i) - - 10,792,335 10,792 Shares issued on conversion and settlement of debt (ii)(iii) - - 1,012,142 1,012 Shares issued on the exercise of options (iv) - - 1,310,734 1,311 Balance at end of the period 50,000,000 50,000 49,737,096 49,737 Common Shares: Balance at beginning of the period - - - - Shares issued as Merger consideration (vii) 6,000,063 6,000 - - Shares issued under private placement (vi)(viii) 9,839,500 9,840 - - Balance at end of the period 15,839,563 15,840 - - TOTAL COMMON SHARES 65,839,563 65,840 - - (i) In April, 2014, the Company completed a private placement issuing 10,792,335 common shares at a price of $0.24 per share for gross proceeds of $2,616,062. A former director of the Company assisted in securing a significant portion of this financing. The Company incurred $11,609 in share issue costs related to the transaction. (ii) In May 2014, the Company issued 436,908 common shares in exchange for the settlement of $115,223 of unsecured debt. (iii) In June, 2014, the Company issued 575,234 common shares on conversion of the convertible secured promissory note (Note 6). The note plus accrued interest totaled $124,523 and was converted at a 20% discount to the April 2014 private placement. (iv) In June 2014, the Company issued 1,310,734 common shares for the exercise of stock options. The Company received cash of $228,875. (v) On February 25, 2015, 262,904 common shares were issued to two former lenders connected with a $241,185 loan received and repaid during fiscal 2013. The common shares were valued at $210,323 based on the value of the concurrent private placement (Note 8(vi)), and recorded in stock-based compensation on the consolidated statement of operations and comprehensive loss. As part of the consideration for the initial loan the CTO and COO had transferred 314,560 common shares to the lenders. For contributing the common shares to the lenders, the Company intends to reimburse the CTO and COO 320,000 common shares. As at March 31, 2016, these shares have not yet been issued. (vi) Concurrently with the closing of the Merger on February 26, 2015, the Company issued 7,735,750 units (the “Units”) for gross proceeds of $6,188,600 (the “First Closing”) (including $500,000 of outstanding bridge loans converted into Units at the offering price) at a purchase price of $0.80 per Unit (the “Purchase Price”) in a private placement offering (the “Offering”). Each Unit consists of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other costs related to the transaction of $848,822 and issued 773,575 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant derivative liability on the consolidated balance sheet (Note 10). After deducting the value of the warrants and the share issue costs, $4,789,404 was attributed to the value of the common shares. (vii) Immediately following the Merger and the First Closing, 6,000,063 common shares were held by existing Drywave stockholders, 7,735,750 were held by the investors in the Offering and Bionik Canada shareholders held an equivalent of 50,000,000 shares of the common shares through their ownership of 100% of the Exchangeable Shares which are held in 1 Special Preferred Share. The Special Preferred Share votes on behalf of the 50,000,000 Exchangeable Shares alongside the common shares of the Company as a single class. (viii) On March 27, 2015, the Company issued 1,212,500 Units for gross proceeds of $970,000 to accredited investors in a second closing (the “Second Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other costs related to the Second Closing of $141,100 and issued 121,250 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant liability on the consolidated balance sheet (Note 10). The fair value of the warrants exceeded the net proceeds received upon closing and as a result $207,425 was recorded as a loss on initial recognition of the warrants and included in the change in fair value of warrant derivative liability on the consolidated statements of operations and comprehensive loss. (ix) On March 31 2015, the Company issued 891,250 Units for gross proceeds of $713,000 to accredited investors in a third closing (the “Third Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other costs related to the Third Closing of $97,099 and issued 89,125 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant liability on the consolidated balance sheet (Note 10). The fair value of the warrants exceeded the net proceeds received upon closing and as a result $143,389 was recorded as a loss on initial recognition of the warrants and included in the change in fair value of warrant derivative liability on the consolidated statements of operations and comprehensive loss. (x) On April 21, 2015, the Company issued 3,115,000 Units for gross proceeds of $2,492,000 to accredited investors in a fourth closing (the “Fourth Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other related to the Fourth Closing of $338,960 and issued 311,500 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant liability on the consolidated balance sheet (Note 10). The fair value of the warrants exceeded the net proceeds received upon closing and as a result $435,682 was recorded as a loss on initial recognition of the warrants and included in the change in fair value of warrant derivative liability on the consolidated statements of operations and comprehensive loss. (xi) On May 27, 2015, the Company issued 1,418,750 Units for gross proceeds of $1,135,000 to accredited investors in a fifth closing (the “Fifth Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other costs related to the Fifth Closing of $147,566 and issued 141,875 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant liability on the consolidated balance sheet (Note 10). The fair value of the warrants exceeded the net proceeds received upon closing and as a result $37,739 was recorded as a loss on initial recognition of the warrants and included in the change in fair value of warrant derivative liability on the consolidated statements of operations and comprehensive loss. (xii) On June 30, 2015, the Company issued 2,035,000 Units for gross proceeds of $1,628,000 to accredited investors in a sixth and final closing (the “Sixth Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other costs related to the Sixth Closing of $211,656 and issued 203,500 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant liability on the consolidated balance sheet (Note 10). The fair value of the warrants exceeded the net proceeds received upon closing and as a result $74,625 was recorded as a loss on initial recognition of the warrants and included in the change in fair value of warrant derivative liability on the consolidated statements of operations and comprehensive loss. (xiii) During the year ended December 31, 2015, the Company entered into service agreements which included paying some of the fees in common shares. During the year ended December 31, 2015, the Company issued 20,000 shares pursuant to these commitments valued at $31,000 and included in share-based compensation. In addition, pursuant to these commitments the Company was obligated to issue 53,223 common shares valued at $98,900. During the three month period ended March 31, 2016 the 53,223 common shares related to services provided in 2015 were issued. As a result $98,900 recorded as shares to be issued at December 31, 2015 was reclassified to additional paid in capital. During the three months ended March 31, 2016, 64,248 common shares were issued related to investor relations and consulting services provided in 2016 valued at $75,600. (xiv) In February 2016, 45,508 common shares were issued as a result of a cashless exercise of 148,787 warrants with an exercise price of $0.80 under the terms of the warrant agreement. The value of the warrants on exercise was attributed to the shares on exercise. As a result $60,966 was reclassified from warrant derivative liability to additional paid in capital. Special Voting Preferred Share In connection with the Merger (Note 1), on February 26, 2015, the Company entered into a voting and exchange trust agreement (the “Trust Agreement”). Pursuant to the Trust Agreement, the Company issued one Special Voting Preferred Share to the Trustee, and the parties created a trust for the Trustee to hold the Special Voting Preferred Share for the benefit of the holders of the Exchangeable Shares (the “Beneficiaries”). Pursuant to the Trust Agreement, the Beneficiaries will have voting rights in the Company equivalent to what they would have had, had they received shares of common stock in the same amount as the Exchangeable Shares held by the Beneficiaries. In connection with the Merger and the Trust Agreement, effective February 20, 2015, the Company filed a certificate of designation of the Special Voting Preferred Share (the “Special Voting Certificate of Designation”) with the Delaware Secretary of State. Pursuant to the Special Voting Certificate of Designation, one share of the Company’s blank check preferred stock was designated as Special Voting Preferred Share. The Special Voting Preferred Share entitles the Trustee to exercise the number of votes equal to the number of Exchangeable Shares outstanding on a one-for-one basis during the term of the Trust Agreement. The Special Voting Preferred Share is not entitled to receive any dividends or to receive any assets of the Company upon liquidation, and is not convertible into common shares of the Company. The voting rights of the Special Voting Preferred Share will terminate pursuant to and in accordance with the Trust Agreement. The Special Voting Preferred Share will be automatically cancelled at such time as no Exchangeable Shares are held by a Beneficiary.

STOCK OPTIONS

STOCK OPTIONS	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	10. STOCK OPTIONS The purpose of the Company’s stock option plan, is to attract, retain and motivate persons of training, experience and leadership to the Company, including their directors, officers and employees, and to advance the interests of the Company by providing such persons with the opportunity, through share options, to acquire an increased proprietary interest in the Company. Options may be granted in respect of authorized and unissued shares, provided that the aggregate number of shares reserved for issuance upon the exercise of all Options granted under the Plan, shall not exceed 10,800,000 On April 11, 2014 and June 20, 2014 the Company issued 657,430 264,230 0.165 0.23 125,824 531,606 264,230 230,930 118,957 62,912 3,658 176 On July 1, 2014, the Company issued 2,972,592 0.23 7 1,259,487 990,864 On February 17, 2015, the Company issued 314,560 0.23 136,613 110,100 7,400 On November 24, 2015, the Company issued 650,000 694,384 250,000 62,317 35,609 On December 14, 2015, the Company issued 2,495,000 1,260,437 25,000 40,000 100,308 On April 21, 2016, the Company issued 3,000,000 3,895,000 1,000,000 0.25 1,000,000 0.95 1,000,000 1.05 2,582,890 On April 26, 2016, the Company issued 250,000 1.00 213,750 During the three month period ended June 30, 2016, the Company recorded $ 159,818 1,297,558 Grant date Expected life Risk Dividend Forfeiture Expected Grant date February 17, 2015 4.50 1.59 % 0 % 0 % 114 % $ 136,613 July 1, 2014 3.90 1.59 % 0 % 0 % 114 % $ 1,259,487 June 20, 2014 6.07 1.59 % 0 % 0 % 114 % $ 118,957 April 11, 2014 4.14 1.59 % 0 % 0 % 114 % $ 230,930 November 24, 2015 6.5 1.59 % 0 % 0 % 114 % $ 694,384 December 14, 2015 6.5 1.59 % 0 % 0 % 114 % $ 1,260,437 April 21, 2016 0.59 – 9.51 1.59 % 0 % 0 % 114 % $ 2,582,890 April 26, 2016 6.9 1.59 % 0 % 0 % 114 % $ 213,750 Number of Options Weighted-Average Outstanding, December 31, 2015 6,960,609 0.59 Cancelled (355,729) 0.97 Outstanding, March 31, 2016 6,604,880 0.57 Issued 3,250,000 0.77 Cancelled (123,895) 0.45 Outstanding, June 30, 2016 9,730,985 0.64 Exercise Price ($) Number of Options Expiry Date Number of 0.165 374,324 April 1, 2021 374,324 0.23 99,610 June 20, 2021 99,610 0.23 2,972,592 July 1, 2021 2,972,592 0.23 204,460 February 17, 2022 136,314 1.22 400,000 November 24, 2022 - 1.00 2,430,000 December 14, 2022 - 1.00 250,000 April 26, 2023 - 0.25 906,077 July 28, 2025 906,077 0.25 93,923 December 30, 2025 59,158 0.95 9,486 February 2, 2017 9,486 0.95 111,937 March 28, 2023 111,937 0.95 31,620 March 3, 2024 31,620 0.95 15,810 March 14, 2024 15,810 0.95 82,213 September 30, 2024 82,213 0.95 7,431 June 2, 2025 7,431 0.95 671,859 July 29, 2025 671,859 0.95 69,643 December 30, 2025 8,193 1.05 36,697 February 2, 2017 36,697 1.05 423,642 March 28, 2023 423,642 1.05 122,324 March 3, 2024 122,324 1.05 70,548 March 14, 2024 61,162 1.05 318,042 September 30, 2024 318,042 1.05 28,747 June 2, 2025 28,747 9,730,985 6,477,238 The weighted-average remaining contractual term of the outstanding options is 6.50 (June 30, 2015 – 6.02) and for the options that are exercisable 6.48 (June 30, 2015 – 6.00).	9. STOCK OPTIONS The purpose of the Company’s stock option plan, is to attract, retain and motivate persons of training, experience and leadership to the Company, including their directors, officers and employees, and to advance the interests of the Company by providing such persons with the opportunity, through share options, to acquire an increased proprietary interest in the Company. Options may be granted in respect of authorized and unissued shares, provided that the aggregate number of shares reserved for issuance upon the exercise of all Options granted under the Plan, shall not exceed 10,800,000 On April 11, 2014 and June 20, 2014 the Company issued 657,430 264,230 0.165 0.23 125,824 657,430 531,606 264,230 230,930 118,957 On July 1, 2014, the Company issued 2,972,592 0.23 7 1,259,487 On February 17, 2015, the Company issued 314,560 0.23 136,613 On November 24, 2015, the Company issued 650,000 694,384 On December 14, 2015, the Company issued 2,495,000 1,260,437 During the three and twelve month period ended March 31, 2016 the Company recorded $ 158,244 1,464,837 1,467,907 112,573 Grant date Expected life Risk Dividend Forfeiture Expected Grant date February 17, 2015 5 1.59 % 0 % 0 % 114 % $ 136,613 July 1, 2014 4.35 1.59 % 0 % 0 % 114 % $ 1,259,487 June 20, 2014 6.32 1.59 % 0 % 0 % 114 % $ 118,957 April 11, 2014 4.14 1.59 % 0 % 0 % 114 % $ 230,930 November 24, 2015 7 1.59 % 0 % 0 % 114 % $ 694,384 December 14, 2015 7 1.59 % 0 % 0 % 114 % $ 1,260,437 Number of Options Weighted-Average Outstanding, December 31, 2013 1,310,665 0.19 Exercised (1,310,665) 0.19 Issued 3,894,252 0.22 Cancelled (125,824) 0.17 Outstanding, December 31, 2014 3,768,428 0.22 Cancelled as a result of Merger (3,768,428) 0.22 Re-issued as part of Merger 3,768,428 0.22 Issued 314,560 0.23 Outstanding March 31, 2015 4,082,988 0.22 Issued 3,145,000 1.05 Cancelled (267,379) 0.22 Outstanding, December 31, 2015 6,960,609 0.59 Cancelled (355,729) 0.97 Outstanding, March 31, 2016 6,604,880 0.57 Exercise Price ($) Number of Options Expiry Date Number of 0.165 437,236 April 1, 2021 291,492 0.23 99,610 June 20, 2021 67,107 0.23 2,972,592 July 1, 2021 2,972,592 0.23 225,442 February 17, 2022 157,285 1.22 400,000 November 24, 2022 - 1.00 2,470,000 December 14, 2022 - 6,604,880 3,488,476 The weighted-average remaining contractual term of the outstanding options is 5.89 6.27 6.16 6.47 5.26 6.31 5.49 6.33

WARRANTS

WARRANTS	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
Warrants and Rights Note Disclosure [Abstract]
Shareholders Equity And Share Based Payments Stock Warrant [Text Block]	11. WARRANTS Number of Warrants Weighted-Average Outstanding and exercisable, March 31, 2015 10,823,450 1.35 Issued 7,225,625 1.35 Outstanding and exercisable, December 31, 2015 18,049,075 1.35 Exercised (148,787) (0.80) Outstanding and exercisable, March 31, 2016 17,900,288 1.35 Exercised (262,045) (0.80) Outstanding and exercisable, June 30, 2016 17,638,243 1.36 In February 2016, a warrant holder exercised 148,787 45,508 262,045 51,249 Common share purchase warrants Exercise Number of Expiry Date 1.40 7,735,750 February 26, 2019 1.40 1,212,500 March 27, 2019 1.40 891,250 March 31, 2019 1.40 Note 9(i) 3,115,000 April 21, 2019 1.40 Note 9 (ii) 1,418,750 May 27, 2019 1.40 Note 9(iii) 2,035,000 June 30, 2019 0.80 Note (9 i to iii) 1,229,993 February 26, 2019 17,638,243 The weighted-average remaining contractual term of the outstanding warrants is 2.52 (March 31, 2016 – 2.77). Exchangeable share purchase warrants In 2014, the Company repaid loans of $180,940 plus accrued interest of $12,138 owing to investors introduced by Pope and Co. As part of this transaction the Company was committed to issue these lenders warrants exercisable into 349,522 Exchangeable Shares at an exercise price of $0.23 per share for a period ending March 21, 2017. During the year ended March 31, 2015, the Company issued these warrants. Warrant derivative liability The Company’s outstanding common share purchase warrants include price protection provisions that allow for a reduction in the exercise price of the warrants in the event the Company subsequently issues common stock or options, rights, warrants or securities convertible or exchangeable for shares of common stock at a price lower than the exercise price of the warrants. Simultaneously with any reduction to the exercise price, the number of shares of common stock that may be purchased upon exercise of each of these warrants shall be increased based on a pre-defined formula. In addition, prior to the effectiveness of certain resale registration statements or if any such registration statements are no longer effective, the holder of the Company’s warrants, at their option, may exercise all or any part of the warrants in a “cashless” or “net-issue” exercise. The Company has the option to redeem the warrants for $ 0.001 The Company’s derivative instruments have been measured at fair value at inception and at each reporting period using a simulation model. The Company recognizes all of its warrants with price protection on its consolidated balance sheet as a derivative liability. Number Value ($) Balance at March 31, 2015 10,823,450 8,382,648 Warrants issued in April 21, 2015 financing 3,426,500 2,588,722 Warrants issued in May 27, 2015 financing 1,560,625 1,025,173 Warrants issued in June 30, 2015 financing 2,238,500 1,490,969 Change in fair value of warrant derivative liability - (7,419,643) Balance at December 31, 2015 18,049,075 6,067,869 Fair value of warrants exercised (148,787) (60,966) Change in fair value of warrant derivative liability - (870,913) Balance at March 31, 2016 17,900,288 5,135,990 Change in fair value of warrant derivative liability - 434,621 Fair value of warrants exercised (262,045) (43,562) Balance at June 30, 2016 17,638,243 5,527,049 During the three month period ended June 30, 2016, the Company recorded a loss of $391,059 on re-measurement of the warrant liability to fair value. The change is recorded as a change in fair value of warrant derivative liability within the Company’s consolidated statement of operations and comprehensive (loss) income. Grant date Number of Expected Exercise Risk Dividend Expected Fair At Inception: February 26, 2015 7,735,750 4 1.4 0.44 % 0 % 51.83 % 464,784 February 26, 2015 773,575 4 0.8 0.44 % 0 % 51.83 % 85,590 March 27, 2015 1,212,500 3.92 1.4 0.43 % 0 % 52.37 % 950,913 March 27, 2015 121,250 3.92 0.8 0.43 % 0 % 52.37 % 85,412 March 31, 2015 891,250 3.91 1.4 0.41 % 0 % 52.45 % 696,582 March 31, 2015 89,125 3.91 0.8 0.41 % 0 % 52.45 % 62,708 April 21, 2015 3,115,000 3.85 1.4 0.68 % 0 % 51.54 % 2,371,956 April 21, 2015 311,500 3.85 0.8 0.68 % 0 % 51.54 % 216,766 May 27, 2015 1,418,750 3.76 1.4 0.46 % 0 % 51.74 % 933,065 May 27, 2015 141,875 3.76 0.8 0.46 % 0 % 51.74 % 92,108 June 30, 2015 2,035,000 3.66 1.4 0.37 % 0 % 52.94 % 1,356,512 June 30, 2015 203,500 3.66 0.8 0.37 % 0 % 52.94 % 134,457 At year end March 31, 2016: March 31, 2016 16,408,250 2.91 1.4 0.21 % 0 % 62.96 % 4,585,539 March 31, 2016 1,492,038 2.91 0.8 0.21 % 0 % 62.96 % 550,451 At Period End: June 30, 2016 16,408,250 2.66 1.4 0.26 % 0 % 70.77 % 5,003,830 June 30, 2016 1,229,993 2.66 0.8 0.26 % 0 % 70.77 % 523,219 In addition to the forgoing, the Company also utilized a holding cost to approximate the impact of a holder of the warrant to maintain a hedging strategy in which they maintained a short position. On analysis of comparable companies and other information the Company has determined that the use of 2.25% in the simulation model is a reasonable assumption. The warrant derivative liability is classified within Level 3 of the fair value hierarchy because on initial recognition and again at each reporting period, it was valued using these significant inputs and assumptions that are unobservable in the market. Changes in the values assumed and used in the simulation model can materially affect the estimate of fair value. Generally, an increase in the market price of the Company’s common shares, an increase in the volatility of the Company’s common shares and an increase in the expected life would result in a directionally similar change in the estimated fair value of the warrant derivative liability. An increase in the risk free rate would result in a decrease in the fair value of the warrant derivative liability. The expected life is based on the remaining contractual term of the warrants. The risk free rate was based on U.S. treasury-note yields with terms commensurate with the remaining term of the warrants. Expected volatility over the expected term of the warrants is estimated based on consideration of historical volatility and other information. In addition to the assumptions above, the Company also took into consideration the probability of the Company’s participation in another round of financing, the type of such financing and the range of the stock price for the financing at that time. At each increment of the simulation, the daily volume weighted-average price was calculated. If this amount was 200% greater than the exercise price of the warrants at the time, and this threshold was maintained for 20 consecutive days, the simulation assumed the trigger of the Company’s option to redeem and the exercise of the warrants by the holder within thirty days. In the circumstance where the redemption was not triggered the warrant was valued at its discounted intrinsic value at maturity.	10. WARRANTS Number of Warrants Weighted-Average Outstanding and exercisable, December 31, 2014 - - Issued 10,823,450 1.35 Outstanding and exercisable, March 31, 2015 10,823,450 1.35 Issued 7,225,625 1.35 Outstanding and exercisable, December 31, 2015 18,049,075 1.35 Issued 18,049,075 1.35 Exercised (148,787) (0.80) Outstanding and exercisable, March 31, 2016 17,900,288 1.35 In February 2016, a warrant holder exercised 148,787 45,508 Common share purchase warrants Exercise Number of Expiry Date 1.40 Note 8(vi) 7,735,750 February 26, 2019 0.80 Note 8(vi) 773,575 February 26, 2019 1.40 Note 8(viii) 1,212,500 March 27, 2019 0.80 Note 8(viii) 121,250 February 26, 2019 1.40 Note 8(ix) 891,250 March 31, 2019 0.80 Note 8(ix) 89,125 February 26, 2019 1.40 Note 8(x) 3,115,000 April 21, 2019 0.80 Note 8(x) 311,500 February 26, 2019 1.40 Note 8(xi) 1,418,750 May 27, 2019 0.80 Note 8(xi) 141,875 February 26, 2019 1.40 Note 8(xii) 2,035,000 June 30, 2019 0.80 Note 8(xii) 54,713 February 26, 2019 17,900,288 The weighted-average remaining contractual term of the outstanding warrants is 2.77 3.93 3.16 Exchangeable share purchase warrants In 2014 the Company repaid loans of $ 180,940 12,138 349,522 0.23 Warrant derivative liability The Company’s outstanding common share purchase warrants include price protection provisions that allow for a reduction in the exercise price of the warrants in the event the Company subsequently issues common stock or options, rights, warrants or securities convertible or exchangeable for shares of common stock at a price lower than the exercise price of the warrants. Simultaneously with any reduction to the exercise price, the number of shares of common stock that may be purchased upon exercise of each of these warrants shall be increased based on a pre-defined formula. In addition, prior to the effectiveness of certain resale registration statements or if any such registration statements are no longer effective, the holder of the Company’s warrants, at their option, may exercise all or any part of the warrants in a “cashless” or “net-issue” exercise. The Company has the option to redeem the warrants for $0.001 per warrant if the daily volume weighted-average price of the common shares is 200% or more of the exercise price for twenty consecutive trading days provided there is an effective registration statement covering the common shares available throughout the thirty day period after the redemption date. The warrant holders then have thirty days to exercise the warrants or receive the redemption amount. The Company’s derivative instruments have been measured at fair value at inception and at each reporting period using a simulation model. The Company recognizes all of its warrants with price protection on its consolidated balance sheet as a derivative liability. Number Value ($) Warrants issued in February 26, 2015 financing Note 8(vi) 8,509,325 550,374 Warrants issued in March 27, 2015 financing Note 8(viii) 1,333,750 1,036,325 Warrants issued in March 31, 2015 financing Note 8(ix) 980,375 759,290 Change in fair value of warrant derivative liability 6,036,659 Balance at March 31, 2015 8,382,648 Warrants issued in April 21, 2015 financing Note 8(x) 3,426,500 2,588,722 Warrants issued in May 27, 2015 financing Note 8(xi) 1,560,625 1,025,173 Warrants issued in June 30, 2015 financing Note 8(xii) 2,238,500 1,490,969 Change in fair value of warrant derivative liability (7,419,643) Balance at December 31, 2015 6,067,869 Fair value of warrants exercised (60,966) Change in fair value of warrant derivative liability (870,913) Balance at March 31, 2016 5,135,990 During the year ended March 31, 2016 and December 31, 2015, the Company recorded a loss of $ 548,046 8,290,601 1,382,984 7,742,555 484,124 During the three month period ended March 31, 2016, $ 870,913 Grant date Number of Expected Exercise Risk Dividend Expected Fair At Inception: February 26, 2015 7,735,750 4 1.4 0.44 % 0 % 51.83 % 464,784 February 26, 2015 773,575 4 0.8 0.44 % 0 % 51.83 % 85,590 March 27, 2015 1,212,500 3.92 1.4 0.43 % 0 % 52.37 % 950,913 March 27, 2015 121,250 3.92 0.8 0.43 % 0 % 52.37 % 85,412 March 31, 2015 891,250 3.91 1.4 0.41 % 0 % 52.45 % 696,582 March 31, 2015 89,125 3.91 0.8 0.41 % 0 % 52.45 % 62,708 April 21, 2015 3,115,000 3.85 1.4 0.68 % 0 % 51.54 % 2,371,956 April 21, 2015 311,500 3.85 0.8 0.68 % 0 % 51.54 % 216,766 May 27, 2015 1,418,750 3.76 1.4 0.46 % 0 % 51.74 % 933,065 May 27, 2015 141,875 3.76 0.8 0.46 % 0 % 51.74 % 92,108 June 30, 2015 2,035,000 3.66 1.4 0.37 % 0 % 52.94 % 1,356,512 June 30, 2015 203,500 3.66 0.8 0.37 % 0 % 52.94 % 134,457 At Period End: March 31, 2016 16,408,250 2.91 1.4 0.21 % 0 % 62.96 % 4,585,539 March 31, 2016 1,492,038 2.91 0.8 0.21 % 0 % 62.96 % 550,451 At Period End: December 31, 2015 16,408,250 3.16 1.4 0.65 % 0 % 53.58 % 5,315,536 December 31, 2015 1,640,825 3.16 0.8 0.65 % 0 % 53.58 % 752,333 At Period End: March 31, 2015 9,839,500 3.91 1.4 0.41 % 0 % 52.45 % 7,690,340 March 31, 2015 983,950 3.91 0.8 0.41 % 0 % 52.45 % 692,308 In addition to the forgoing, the Company also utilized a holding cost to approximate the impact of a holder of the warrant to maintain a hedging strategy in which they maintained a short position. On analysis of comparable companies and other information the Company has determined that the use of 2.25 The warrant derivative liability is classified within Level 3 of the fair value hierarchy because on initial recognition and again at each reporting period, it was valued using these significant inputs and assumptions that are unobservable in the market. Changes in the values assumed and used in the simulation model can materially affect the estimate of fair value. Generally, an increase in the market price of the Company’s common shares, an increase in the volatility of the Company’s common shares and an increase in the expected life would result in a directionally similar change in the estimated fair value of the warrant derivative liability. An increase in the risk free rate would result in a decrease in the fair value of the warrant derivative liability. The expected life is based on the remaining contractual term of the warrants. The risk free rate was based on U.S. treasury-note yields with terms commensurate with the remaining term of the warrants. Expected volatility over the expected term of the warrants is estimated based on consideration of historical volatility and other information. In addition to the assumptions above, the Company also took into consideration the probability of the Company’s participation in another round of financing, the type of such financing and the range of the stock price for the financing at that time. At each increment of the simulation, the daily volume weighted-average price was calculated. If this amount was 200

INCOME TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	INCOME TAXES 3 months Year Year ended Nine $ $ $ $ U.S. 183,461 4,706,413 (2,372,510) - Canada (1,187,553) (3,670,265) (3,221,396) (2,464,747) (1,004,092) 1,036,148 (5,593,906) (2,464,747) Reconciliation of the statutory tax rate of 35 26.5 3 months Year ended Year ended Nine $ $ $ $ Net (loss) income for the period before recovery of income taxes (1,004,092) 1,036,148 (5,593,906) (2,464,747) Statutory rate 35 % 35 % 35 % 26.5 % Expected income tax (recovery) expense (351,432) 362,652 (1,957,867) (653,158) Tax rate changes and other basis adjustments (162,267) 195,108 364,651 (29,109) Change in fair value of derivative liability (304,835) (2,709,894) (169,443) Stock-based compensation 55,350 512,693 587,381 - Non-deductible expenses (99,642) (12,073) 227,068 193,305 Change in valuation allowance 862,826 1,651,514 948,210 488,962 Recovery of income taxes - - - - March 31, March 31, December 31, December 31, $ $ $ $ Property and equipment 52,331 34,556 47,495 36,940 Share issue costs 3,586 5,838 3,877 162,350 SR&ED pool 400,557 103,799 340,585 7,137 Other 215,202 32,447 39,947 18,621 Non-capital losses – Canada 1,587,439 977,178 1,149,389 812,522 Net operating losses - U.S. 589,491 43,274 404,487 - Valuation allowance (2,848,606) (1,197,092) (1,985,780) (1,037,570) - - - - The Company has non-capital losses in its Canadian subsidiary of approximately $ 5,990,000 1,684,261 Income taxes are provided based on the liability method, which results in deferred tax assets and liabilities arising from temporary differences. Temporary differences are differences between the tax basis of assets and liabilities and their reported amounts in the consolidated financial statements that will result in taxable or deductible amounts in future years. The liability method requires the effect of tax rate changes on current and accumulated deferred taxes to be reflected in the period in which the rate change was enacted. The liability method also requires that deferred tax assets be reduced by a valuation allowance unless it is more likely than not that the assets will be realized. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest accrued on uncertain tax positions as well as interest received from favorable tax settlements within interest expense. The Company recognizes penalties accrued on unrecognized tax benefits within general and administrative expenses. As of March 31, 2016, the Company had no uncertain tax positions. United States - Federal 2013 – present United States – State 2013 – present Canada – Federal 2012 - present Canada – Provincial 2012 - present

ROYALTY AGREEMENT

ROYALTY AGREEMENT	3 Months Ended
	Jun. 30, 2016
Royalty Agreement [Abstract]
Royalty Agreement [Text Block]	12. ROYALTY AGREEMENT Prior to the acquisition of IMT in April 2012, IMT entered into a Patent License Agreement with an unrelated third party (the “Licensee”). Under the terms of the perpetual license agreement, the Company will receive royalties from the Licensee based on a licensed product sold by the Licensee. There was no royalty income in 2016 or 2015 under the terms of the agreement.

LICENSING AGREEMENTS

LICENSING AGREEMENTS	3 Months Ended
	Jun. 30, 2016
Licensing Agreements [Abstract]
Licensing Agreements Disclosure [Text Block]	13. LICENSING AGREEMENTS The Company’s subsidiary maintains a licensing agreement with the Massachusetts Institute of Technology (“MIT”) for exclusive rights to utilize certain of MIT’s patented technology. The licensing agreement remains in effect until the expiration or abandonment of all patent rights and patent applications filed that are included under license, the last of which patent rights expires in November 2024. The agreement provides the Company with the option to sublicense the rights under the agreement. Under the terms of the agreement, as amended, royalties are payable to MIT based on 3% of certain domestic product sales and 1.5% of certain international product sales, as defined, and 50% of all sublicense income. The Company recognized $nil of royalty expense under this agreement during the three months ended June 30, 2016. At June 30, 2016, the Company had accrued royalty and related amounts payable to MIT of $31,388 included in accrued liabilities on the condensed interim balance sheets. One of the Company’s directors is an employee of MIT as well as the Company’s Chief Science Officer. The Company maintains a second licensing agreement with the same director noted above and an unrelated third party for exclusive rights to utilize certain patented technology. The Company has exclusive rights to the patents and related applications, as defined, until expiration in May 2027. The agreement provides the Company with the option to sublicense the rights under the agreement. Under the terms of the agreement royalties are payable to the patent holders based on 1% of net sales, as defined, and 50% of all sublicense income. There have been no sales under this agreement through June 30, 2016.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	14. COMMITMENTS AND CONTINGENCIES Contingencies From time to time, the Company may be involved in a variety of claims, suits, investigations and proceedings arising in the ordinary course of our business, collection claims, breach of contract claims, labor and employment claims, tax and other matters. Although claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, the Company believes that the resolution of current pending matters will not have a material adverse effect on its business, financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on the Company because of legal costs, diversion of management resources and other factors.	12. COMMITMENTS AND CONTINGENCIES Contingencies From time to time, the Company may be involved in a variety of claims, suits, investigations and proceedings arising in the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, the Company believes that the resolution of current pending matters will not have a material adverse effect on its business, financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on the Company because of legal costs, diversion of management resources and other factors.

RISK MANAGEMENT

RISK MANAGEMENT	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	15. RISK MANAGEMENT The Company’s cash balances are maintained in two banks in Canada and a Canadian Bank subsidiary in the US and a US Bank. Deposits held in banks in Canada are insured up to $100,000 CAD per depositor for each bank by The Canada Deposit Insurance Corporation, a federal crown corporation. Actual balances at times may exceed these limits. Interest Rate Risk Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in the interest rates. The Company has minimal exposure to fluctuations in the market interest rate. In seeking to minimize the risks from interest rate fluctuations, the Company manages exposure through its normal operating and financing activities. Liquidity Risk Liquidity risk is the risk that the Company will incur difficulties meeting its financial obligations, as they are due. The Company’s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due. Accounts payable and accrued liabilities are due within the current operating period. The Company has funded its operations through the issuance of capital stock, convertible debt and loans in addition to grants and investment tax credits received from the Government of Canada.	13. RISK MANAGEMENT The Company’s cash balances are maintained in two banks in Canada and a Canadian Bank subsidiary in the US. Deposits held in banks in Canada are insured up to $ 100,000 Interest Rate Risk Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in the interest rates. The Company has minimal exposure to fluctuations in the market interest rate. In seeking to minimize the risks from interest rate fluctuations, the Company manages exposure through its normal operating and financing activities. Liquidity Risk Liquidity risk is the risk that the Company will incur difficulties meeting its financial obligations, as they are due. The Company’s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due. Accounts payable and accrued liabilities are due within the current operating period. The Company has funded its operations through the issuance of capital stock, convertible debt and loans in addition to grants and investment tax credits received from the Government of Canada.

(LOSS) PER SHARE

(LOSS) PER SHARE	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	(LOSS) PER SHARE Common share equivalents, options and warrants are were excluded from the computation of diluted loss per share for the three month periods ended March 31, 2016 and 2015 (unaudited), the years ended December 31, 2015 and March 31, 2015 (unaudited) and the nine month period ended December 31, 2014 as their effects are anti-dilutive. Numerator Net income $ 1,036,148 Change in fair value of warrant derivative liability (7,742,555) Net (loss) used in computation of diluted EPS $ (6,706,407) Denominator Basic weighted average number of shares outstanding 71,554,822 Warrants 8,429,435 Diluted weighted average number of shares outstanding 79,984,257 Diluted loss per share $ (0.08)

TRANSITION PERIOD COMPARATIVE D

TRANSITION PERIOD COMPARATIVE DATA	3 Months Ended
	Mar. 31, 2016
Transition Period Comparative Data [Abstract]
Transition Period Comparative Data [Text Block]	15. TRANSITION PERIOD COMPARATIVE DATA Three months March 31, 2015 $ Operating Data: Expenses Research and development 435,671 Professional and consulting fees 261,350 General and administrative 167,747 Depreciation 10,412 Share-based compensation expense 371,637 1,246,817 Other expenses (income) Interest expense 179 Other income (323) Change in fair value of warrant derivative liability 6,387,473 Total other expense (income) 6,387,329 Net loss for the period (7,634,146) Foreign exchange translation adjustment for the period 24,799 Net loss and comprehensive loss for the period (7,609,347) Loss per share - basic and diluted (0.14) Weighted average number of shares outstanding – basic and diluted 52,726,746 Cash flow Data: Net cash used in operating activities (825,483) Net cash used in investing activities (38,820) Net cash provided by financing activities 6,788,988 Effects of foreign currency exchange rate changes (9,510) Net increase in cash and cash equivalents for the period 5,915,175

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	16. SUBSEQUENT EVENTS (a) In July 2016, the Company received a Canadian refundable tax credit totalling $ 403,889 (b) The Company granted 750,000 1.00	SUBSEQUENT EVENTS 1) Subsequent to March 31, 2016, the Company issued 70,000 70,000 2) Subsequent to March 31, 2016, 51,249 262,045 0.80 3) On April 21, 2016, the Company acquired 100 Mergerco Inc., a Massachusetts corporation and a wholly owned subsidiary of the Company (“Merger Subsidiary”), providing for the merger (“Acquisition”) of Merger Subsidiary with and into IMT, with IMT surviving the Merger as a wholly-owned subsidiary of Bionik. Subject to the indemnification and escrow arrangements described in the Merger Agreement, Bionik will issue (or reserve for issuance) an aggregate of 23,650,000 Bionik will also assume each of the 3,895,000 3,000,000 1,000,000 0.25 1,000,000 0.95 1,000,000 1.05 Due to the complexities in identifying and valuing the intangible assets acquired, the Company has not yet finalized the purchase price allocation. At this time the Company is not practicably able to estimate the fair value of each identifiable asset. The Company anticipates the intangible assets to consist of clinical data, sales data, license and patents/technology acquired and any excess to result in goodwill. As at April 21, 2016 $ Consideration Paid: Fair value of 23,650,000 common shares 23,177,000 Fair value of vested stock options 1,573,229 24,750,229 Allocation of purchase price: Net assets acquired (2,129,089) Intangible assets and goodwill 26,879,318 24,750,229 The unaudited supplemental pro forma information for the period presented give effect to the Acquisition as if it had been consummated on April 1, 2015 the start of the March 31, 2016 year-end. The following unaudited supplemental pro forma information are provided for informational purposes only and do not purport to represent what the actual combined results of operations or the combined financial position of the combined company would be had the Merger occurred on the dates assumed, nor are they necessarily indicative of future combined results of operations or combined financial position. The following unaudited supplemental pro forma information have been compiled based on information available to management at this time. The unaudited supplemental pro forma information do not reflect any cost savings or synergies that the management of Interactive Motion Technologies Inc. and Bionik Laboratories Corp. could have achieved if they were together through this period. Year Ended $ Sales 1,919,779 Net loss for the period (15,550,891)

SIGNIFICANT ACCOUNTING POLICI28

SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
Accounting Policies [Abstract]
Unaudited Condensed Consolidated Interim Financial Statements [Policy Text Block]	Unaudited Condensed Consolidated Interim Financial Statements These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements and should be read in conjunction with those annual audited financial statements filed on Form 10-KT for the period ended March 31, 2016. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect adjustments, necessary to present fairly the Company's financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period.
Recently Adopted Accounting Pronouncements [Policy Text Block]	Newly Adopted and Recently Issued Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2017. Early adoption is not permitted. The impact on the consolidated financial statements of adopting ASU 2014-09 will be assessed by management. In August 2014, the FASB issued a new financial accounting standard on going concern, ASU No. 2014-15, “Presentation of Financial Statements – Going Concern (Sub-Topic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The standard provides guidance about management’s responsibility to evaluate whether there is a substantial doubt about the organization’s ability to continue as a going concern. The amendments in this Update apply to all companies. They become effective in the annual period ending after December 15, 2016, with early application permitted. The impact on the consolidated financial statements of adopting ASU 2014-15 will be assessed by management. In September 2015, the FASB issued ASU No. 2015-16, “Simplifying the Accounting for Measurement-Period Adjustments,” which illustrates certain guidance governing adjustments to the provisional amounts recognized at the acquisition date with a corresponding adjustment to goodwill. Such adjustments are required when new information is obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement amounts initially recognized or would have resulted in the recognition of additional assets and liabilities. ASU No. 2015-16 eliminates the requirement to retrospectively account for such adjustments. ASU No. 2015-16 is effective for the fiscal year commencing after December 15, 2016. The Company has adopted this ASU No. 2015-16 as at and for the three and twelve month periods ended March 31, 2016. There was no material effect on the consolidated financial position or the consolidated results of operations and comprehensive loss. In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes,” which requires that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015-17 is effective for the fiscal year commencing after December 15, 2017. The Company does not anticipate that the adoption of ASU No. 2015-17 will have a material effect on the consolidated financial position or the consolidated results of operations. In February 2016, the FASB issued ASU 2016-02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASI 2016-02 will have on the consolidated financial position and the consolidated results of operations. In March 2016, the FASB issued ASU 2016-09, "Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting". Several aspects of the accounting for share-based payment award transaction are simplified, including (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company is still assessing the impact that the adoption of ASI 2016-09 will have on the consolidated financial position and the consolidated results of operations.	Newly Adopted and Recently Issued Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2017. Early adoption is not permitted. The impact on the consolidated financial statements of adopting ASU 2014-09 will be assessed by management. In August 2014, the FASB issued a new financial accounting standard on going concern, ASU No. 2014-15, “Presentation of Financial Statements – Going Concern (Sub-Topic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The standard provides guidance about management’s responsibility to evaluate whether there is a substantial doubt about the organization’s ability to continue as a going concern. The amendments in this Update apply to all companies. They become effective in the annual period ending after December 15, 2016, with early application permitted. The impact on the consolidated financial statements of adopting ASU 2014-15 will be assessed by management.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue upon completion of its products when they are shipped from its place of manufacture.	Revenue Recognition The Company has yet to recognize any revenue. The Company intends to record revenue when it is realized, or realizable and earned. The Company will consider revenue to be realized, or realizable and earned, when the following revenue recognition requirements are met: persuasive evidence of an arrangement exists; the products or services have been accepted by the customer via delivery or acceptance; the sales price is fixed or determinable; and collectability is reasonably assured.
Warrant Derivative Liability Policy [Policy Text Block]	Significant Judgments - Warrant Derivative Liability The Company’s derivative warrant instruments are measured at fair value using a simulation model which takes into account, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock, its expected volatility, holding cost and the risk-free interest rate for the term of the warrant (Note 11). The warrant derivative liability is revalued at each reporting period and changes in fair value are recognized in the condensed consolidated interim statements of operations and comprehensive loss under the caption “Change in fair value of warrant derivative liability”. The selection of the appropriate valuation model and the inputs and assumptions that are required to determine the valuation requires significant judgment and requires management to make estimates and assumptions that affect the reported amount of the related liability and reported amounts of the change in fair value. Actual results could differ from those estimates, and changes in these estimates are recorded when known. As the derivative warrant liability is required to be measured at fair value at each reporting date it is reasonably possible that these estimates and assumptions could change in the near term.	The Company’s derivative warrant instruments are measured at fair value using a simulation model which takes into account, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock, its expected volatility, holding cost and the risk-free interest rate for the term of the warrant (Note 10). The warrant derivative liability is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss under the caption “Change in fair value of warrant derivative liability”.
Standard Product Warranty, Policy [Policy Text Block]	Warranty Reserve and Deferred Warranty Revenue The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the balance sheet and amount to $ 61,380 15,190
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation On April 1, 2015, Bionik Canada and Bionik Acquisition Inc. changed its functional currency from the Canadian Dollar to the U.S. Dollar. This reflects the fact that the majority of the Company’s business is influenced by an economic environment denominated in U.S. currency as well the Company anticipates revenues to be earned in U.S. dollars. The change in accounting treatment is applied prospectively. The functional currency is separately determined for the Company and each of its subsidiaries, and is used to measure the financial position and operating results. The functional currency of the Company and its wholly-owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.	Foreign Currency Translation On April 1, 2015, Bionik Canada and Bionik Acquisition Inc. changed its functional currency from the Canadian Dollar to the U.S. Dollar. This reflects the fact that the majority of the Company’s business is influenced by an economic environment denominated in U.S. currency as well the Company anticipates revenues to be earned in U.S. dollars. The change in accounting treatment was applied prospectively. The functional currency is separately determined for the Company and each of its subsidiaries, and is used to measure the financial position and operating results. The functional currency of the Company and its wholly-owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs which are as observable as possible and the methods most applicable to the specific situation of each company or valued item. The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, other receivables, accounts payable and accrued liabilities, due from related parties approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. As at June 30, 2016, the Company’s warrant derivative liability was measured at fair value at each reporting period using a simulation model based on Level 3 inputs. The Company’s policy is to recognize transfers into and out of Level 3 as of the date of the event or change in the circumstances that caused the transfer. There were no such transfers during the period.	Fair Value of Financial Instruments ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs which are as observable as possible and the methods most applicable to the specific situation of each company or valued item. The carrying amounts reported in the balance sheets for cash and cash equivalents, other receivables, accounts payable, accrued liabilities, and due from related parties’ approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. As at March 31, 2016, the Company’s warrant derivative liability is measured at fair value at each reporting period using a simulation model based on Level 3 inputs. The Company’s policy is to recognize transfers into and out of Level 3 as of the date of the event or change in the circumstances that caused the transfer. There were no such transfers during the year.
Use of Estimates, Policy [Policy Text Block]		Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and changes in these estimates are recorded when known. Significant estimates made by management include: the valuation of the warrant derivative liability and the valuation allowance for deferred tax assets. The selection of the appropriate valuation model to apply to the warrant derivative liability and the related inputs and assumptions that are required to determine that valuation require significant judgment and require management to make estimates and assumptions that affect the reported amount of the related liability and reported amounts of the change in fair value. As the derivative warrant liability is required to be measured at fair value at each reporting date it is reasonably possible that these estimates and assumptions could change in the near term.
Property, Plant and Equipment, Policy [Policy Text Block]		Property and Equipment Property and equipment are recorded at cost. Depreciation is computed using the declining balance method, over the estimated useful lives of these assets. The costs of improvements that extend the life of equipment are capitalized. All ordinary repair and maintenance costs are expensed as incurred. Property and equipment are depreciated as follows: Computer & Electronics 50 Furniture and Fixtures 20 Tools and Parts 20
Government Grants And Input Tax Credit Recoveries [Policy Text Block]		Government Grant and Input Tax Credit Recoveries The Company receives certain grant and input tax credit recoveries from the Canadian government in compensation for eligible expenditures. These are presented as other income in the statement of operations and comprehensive loss as they generally relate to a number of the Company’s operating expenses, such as salaries and benefits, research and development and professional and consulting fees. The recoveries are recognized in the corresponding period when such expenses are incurred and collection of the grant funds is assured.
Cash and Cash Equivalents, Policy [Policy Text Block]		Cash and Cash Equivalents Cash and cash equivalents include highly liquid investments with original terms to maturity of 90 days or less at the date of purchase. For all periods presented cash and cash equivalents consisted entirely of cash.
Research and Development Expense, Policy [Policy Text Block]		Research and Development The Company is engaged in research and development work. Research and development costs are charged as operating expense of the Company as incurred.
Segment Reporting, Policy [Policy Text Block]		Segment Reporting ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for the way that public business enterprises report information about operating segments in the Company’s consolidated financial statements. Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company does not have any reportable segments. All of its operations and assets are domiciled in Canada.
Income Tax, Policy [Policy Text Block]		Income Taxes Income taxes are computed in accordance with the provisions of ASC Topic 740, which requires, among other things, a liability approach to calculating deferred income taxes. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized in its consolidated financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The Company is required to make certain estimates and judgments about the application of tax law, the expected resolution of uncertain tax positions and other matters. In the event that uncertain tax positions are resolved for amounts different than the Company’s estimates, or the related statutes of limitations expire without the assessment of additional income taxes, the Company will be required to adjust the amounts of related assets and liabilities in the period in which such events occur. Such adjustment may have a material impact on Bionik’s income tax provision and results of operations.
Earnings Per Share, Policy [Policy Text Block]		Basic and Diluted Loss Per Share Basic and diluted loss per share has been determined by dividing the net loss available to shareholders for the applicable period by the basic and diluted weighted average number of shares outstanding, respectively. The diluted weighted average number of shares outstanding is calculated as if all dilutive options had been exercised or vested at the later of the beginning of the reporting period or date of grant, using the treasury stock method. Loss per common share is computed by dividing the net loss by the weighted average number of shares of common shares outstanding during the period. Common share equivalents, options and warrants are excluded from the computation of diluted loss per share when their effect is anti-dilutive.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]		The Company follows the ASC Topic 360, which requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable. In performing the review for recoverability, if future undiscounted cash flows (excluding interest charges) from the use and ultimate disposition of the assets are less than their carrying values, an impairment loss represented by the difference between its fair value and carrying value, is recognized. When properties are classified as held for sale they are recorded at the lower of the carrying amount or the expected sales price less costs to sell.
New Accounting Pronouncements, Policy [Policy Text Block]		In March 2016, the FASB issued ASU 2016-09, "Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting". Several aspects of the accounting for share-based payment award transaction are simplified, including (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company is still assessing the impact that the adoption of ASI 2016-09 will have on the consolidated financial position and the consolidated results of operations. In February 2016, the FASB issued ASU 2016-02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASI 2016-02 will have on the consolidated financial position and the consolidated results of operations. In September 2015, the FASB issued ASU No. 2015-16, “Simplifying the Accounting for Measurement-Period Adjustments,” which illustrates certain guidance governing adjustments to the provisional amounts recognized at the acquisition date with a corresponding adjustment to goodwill. Such adjustments are required when new information is obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement amounts initially recognized or would have resulted in the recognition of additional assets and liabilities. ASU No. 2015-16 eliminates the requirement to retrospectively account for such adjustments. ASU No. 2015-16 is effective for the fiscal year commencing on January 1, 2016. The Company has adopted this ASU No. 2015-16 as at and for the three and twelve month periods ended March 31, 2016. There was no material effect on the consolidated financial position or the consolidated results of operations and comprehensive loss.

ACQUISITION (Tables)

ACQUISITION (Tables)	3 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	The following sets forth the preliminary purchase price allocation based on management’s best estimates of fair value, including a summary of major classes of consideration transferred and the recognized amounts of assets acquired and liabilities assumed at the acquisition date. As at April 21, 2016 $ Consideration Paid: Fair value of 23,650,000 common shares (a) 23,177,000 Fair value of vested stock options (b) 2,582,890 25,759,890 Allocation of purchase price: Assets Acquired: Cash and cash equivalents 266,635 Accounts receivable 6,490 Inventories 188,879 Prepaid expenses and other current assets 16,839 Equipment 59,749 Liabilities assumed: Accounts payable (241,299) Accrued liabilities (361,029) Customer deposits (86,487) Demand notes payable (324,894) Promissory notes payable (217,808) Bionik advance (1,436,164) Net assets acquired (2,129,089) Intangible assets and goodwill 27,888,979 25,759,890 (a) The fair value of common shares is based on $ 0.98 (b) The fair value of the vested stock options was determined using the Black Scholes option pricing model with the following key assumptions: a risk free rate of 1.59 0 114
Business Acquisition, Pro Forma Information [Table Text Block]	For the period April 21 - June 30, 2016 (unaudited) Revenue $ 162,588 Net loss and comprehensive loss $ (292,634) The following unaudited pro forma financial information presents combined results of operations for each of the periods presented as if the Merger had been completed April 1, 2016. The pro forma data is for informational purposes only and is not necessarily indicative of the consolidated results of operations of the combined business had the Merger actually occurred on April 1, 2016 or the results of future operations of the combined business. For instance, planned or expected operational synergies following the Merger are not reflected in the pro forma information. Consequently, actual result will differ from the unaudited pro forma information presented below. Three Months Ended June 30, 2016 2015 (unaudited) Revenue $ 166,028 $ 438,414 Net loss and comprehensive loss $ (407,245) $ (124,548) *There were no material or nonrecurring adjustments in the supplemental pro forma revenue or results of operations as shown above.

PREPAID EXPENSES AND OTHER RE30

PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	June 30, March 31, $ $ Prepaid expenses and sundry receivables 75,831 87,979 Prepaid insurance 83,329 107,259 Sales taxes receivable (i) 29,270 36,495 188,430 231,733 (i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.	March 31, March 31, December 31, December 31, $ $ $ $ Prepaid expenses and other receivables 87,979 6,242 120,661 18,172 Prepaid insurance 107,259 126,771 12,966 40,630 Sales taxes receivable (i) 36,495 25,406 54,590 22,328 231,733 158,419 188,217 81,130 i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORIES (Tables)

INVENTORIES (Tables)	3 Months Ended
	Jun. 30, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	June 30, March 31, $ $ Raw Materials 218,047 - Work in Progress 42,212 - 260,259 -

EQUIPMENT (Tables)

EQUIPMENT (Tables)	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Equipment consisted of the following as at June 30, 2016 and March 31, 2016: June 30, 2016 March 31, 2016 Cost Accumulated Net Cost Accumulated Net $ $ $ $ $ $ Computers and electronics 262,853 184,636 78,217 152,246 96,379 55,867 Furniture and fixtures 36,795 24,361 12,434 22,496 10,118 12,378 Demonstration equipment 28,800 1,200 27,600 - - - Manufacturing equipment 84,442 84,442 - - - - Tools and parts 11,422 3,337 8,085 11,422 2,917 8,505 424,312 297,976 126,336 186,164 109,414 76,750	Equipment consisted of the following as at March 31, 2016 and March 31, 2015: March 31, 2016 March 31, 2015 Cost Accumulated Net Cost Accumulated Net $ $ $ $ $ $ Computers and electronics 152,246 96,379 55,867 107,369 33,933 73,436 Furniture and fixtures 22,496 10,118 12,378 23,832 7,689 16,143 Tools and parts 11,422 2,917 8,505 12,100 1,050 11,050 186,164 109,414 76,750 143,301 42,672 100,629 Equipment consisted of the following as at December 31, 2015 and December 31, 2014: December 31, 2015 December 31, 2014 Cost Accumulated Net Cost Accumulated Net $ $ $ $ $ $ Computers and electronics 148,214 84,072 64,142 77,650 27,438 50,212 Furniture and fixtures 23,496 9,478 14,018 24,909 7,325 17,584 Tools and parts 11,422 2,479 8,943 11,913 1,787 10,126 183,132 96,029 87,103 114,472 36,550 77,922

SHARE CAPITAL (Tables)

SHARE CAPITAL (Tables)	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
Stockholders' Equity Note [Abstract]
Schedule of Stockholders Equity [Table Text Block]	June 30, 2016 March 31, 2016 Number of $ Number of $ Exchangeable Shares: Balance beginning and end of the period 50,000,000 50,000 50,000,000 50,000 Common Shares Balance at beginning of the period 22,591,292 22,591 22,428,313 22,428 Shares issued on acquisition (Note 3) 12,339,843 12,339 Shares issued for services (v) 70,000 70 117,471 117 Cashless exercise of warrants (iv) 51,249 51 45,508 46 Balance at end of the period 35,052,384 35,051 22,591,292 22,591 TOTAL COMMON SHARES 85,052,384 85,052 72,591,292 72,591 (i) On April 21, 2015, the Company issued 3,115,000 2,492,000 Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years 311,500 0.80 435,682 (ii) On May 27, 2015, the Company issued 1,418,750 1,135,000 Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years 147,566 141,875 0.80 4 37,739 (iii) On June 30, 2015, the Company issued 2,035,000 1,628,000 Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years 211,656 203,500 0.80 4 74,625 (iv) During the three month period ended June 30, 2016, 51,249 262,045 0.80 43,562 (v) The Company issued 70,000 59,500	March 31, 2016 December 31, 2015 Number of Number of shares $ shares $ Exchangeable Shares: Balance, beginning of period 50,00,000 50,000 50,000,000 50,000 Balance, end of the year 50,000,000 50,000 50,000,000 50,000 Common Shares: Balance, beginning of the period 22,428,313 22,428 15,839,563 15,840 Shares issued under private placement - - (x)-(xii) 6,568,750 6,568 Shares issued for services (xiii) 117,471 117 (xiii) 20,000 20 Cashless exercise of warrants (xiv) 45,508 46 - - Balance, end of the period 22,591,292 22,591 22,428,313 22,428 TOTAL COMMON SHARES 72,591,292 72,591 72,428,313 72,428 March 31, 2015 December 31, 2014 Number of Number of shares $ shares $ Exchangeable Shares: Balance at beginning of period 49,737,096 49,737 36,621,885 36,622 Shares issued for services (v) 262,904 263 - - Shares issued under private placement (i) - - 10,792,335 10,792 Shares issued on conversion and settlement of debt (ii)(iii) - - 1,012,142 1,012 Shares issued on the exercise of options (iv) - - 1,310,734 1,311 Balance at end of the period 50,000,000 50,000 49,737,096 49,737 Common Shares: Balance at beginning of the period - - - - Shares issued as Merger consideration (vii) 6,000,063 6,000 - - Shares issued under private placement (vi)(viii) 9,839,500 9,840 - - Balance at end of the period 15,839,563 15,840 - - TOTAL COMMON SHARES 65,839,563 65,840 - - (i) In April, 2014, the Company completed a private placement issuing 10,792,335 common shares at a price of $0.24 per share for gross proceeds of $2,616,062. A former director of the Company assisted in securing a significant portion of this financing. The Company incurred $11,609 in share issue costs related to the transaction. (ii) In May 2014, the Company issued 436,908 common shares in exchange for the settlement of $115,223 of unsecured debt. (iii) In June, 2014, the Company issued 575,234 common shares on conversion of the convertible secured promissory note (Note 6). The note plus accrued interest totaled $124,523 and was converted at a 20% discount to the April 2014 private placement. (iv) In June 2014, the Company issued 1,310,734 common shares for the exercise of stock options. The Company received cash of $228,875. (v) On February 25, 2015, 262,904 common shares were issued to two former lenders connected with a $241,185 loan received and repaid during fiscal 2013. The common shares were valued at $210,323 based on the value of the concurrent private placement (Note 8(vi)), and recorded in stock-based compensation on the consolidated statement of operations and comprehensive loss. As part of the consideration for the initial loan the CTO and COO had transferred 314,560 common shares to the lenders. For contributing the common shares to the lenders, the Company intends to reimburse the CTO and COO 320,000 common shares. As at March 31, 2016, these shares have not yet been issued. (vi) Concurrently with the closing of the Merger on February 26, 2015, the Company issued 7,735,750 units (the “Units”) for gross proceeds of $6,188,600 (the “First Closing”) (including $500,000 of outstanding bridge loans converted into Units at the offering price) at a purchase price of $0.80 per Unit (the “Purchase Price”) in a private placement offering (the “Offering”). Each Unit consists of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other costs related to the transaction of $848,822 and issued 773,575 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant derivative liability on the consolidated balance sheet (Note 10). After deducting the value of the warrants and the share issue costs, $4,789,404 was attributed to the value of the common shares. (vii) Immediately following the Merger and the First Closing, 6,000,063 common shares were held by existing Drywave stockholders, 7,735,750 were held by the investors in the Offering and Bionik Canada shareholders held an equivalent of 50,000,000 shares of the common shares through their ownership of 100% of the Exchangeable Shares which are held in 1 Special Preferred Share. The Special Preferred Share votes on behalf of the 50,000,000 Exchangeable Shares alongside the common shares of the Company as a single class. (viii) On March 27, 2015, the Company issued 1,212,500 Units for gross proceeds of $970,000 to accredited investors in a second closing (the “Second Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other costs related to the Second Closing of $141,100 and issued 121,250 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant liability on the consolidated balance sheet (Note 10). The fair value of the warrants exceeded the net proceeds received upon closing and as a result $207,425 was recorded as a loss on initial recognition of the warrants and included in the change in fair value of warrant derivative liability on the consolidated statements of operations and comprehensive loss. (ix) On March 31 2015, the Company issued 891,250 Units for gross proceeds of $713,000 to accredited investors in a third closing (the “Third Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other costs related to the Third Closing of $97,099 and issued 89,125 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant liability on the consolidated balance sheet (Note 10). The fair value of the warrants exceeded the net proceeds received upon closing and as a result $143,389 was recorded as a loss on initial recognition of the warrants and included in the change in fair value of warrant derivative liability on the consolidated statements of operations and comprehensive loss. (x) On April 21, 2015, the Company issued 3,115,000 Units for gross proceeds of $2,492,000 to accredited investors in a fourth closing (the “Fourth Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other related to the Fourth Closing of $338,960 and issued 311,500 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant liability on the consolidated balance sheet (Note 10). The fair value of the warrants exceeded the net proceeds received upon closing and as a result $435,682 was recorded as a loss on initial recognition of the warrants and included in the change in fair value of warrant derivative liability on the consolidated statements of operations and comprehensive loss. (xi) On May 27, 2015, the Company issued 1,418,750 Units for gross proceeds of $1,135,000 to accredited investors in a fifth closing (the “Fifth Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other costs related to the Fifth Closing of $147,566 and issued 141,875 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant liability on the consolidated balance sheet (Note 10). The fair value of the warrants exceeded the net proceeds received upon closing and as a result $37,739 was recorded as a loss on initial recognition of the warrants and included in the change in fair value of warrant derivative liability on the consolidated statements of operations and comprehensive loss. (xii) On June 30, 2015, the Company issued 2,035,000 Units for gross proceeds of $1,628,000 to accredited investors in a sixth and final closing (the “Sixth Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other costs related to the Sixth Closing of $211,656 and issued 203,500 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant liability on the consolidated balance sheet (Note 10). The fair value of the warrants exceeded the net proceeds received upon closing and as a result $74,625 was recorded as a loss on initial recognition of the warrants and included in the change in fair value of warrant derivative liability on the consolidated statements of operations and comprehensive loss. (xiii) During the year ended December 31, 2015, the Company entered into service agreements which included paying some of the fees in common shares. During the year ended December 31, 2015, the Company issued 20,000 shares pursuant to these commitments valued at $31,000 and included in share-based compensation. In addition, pursuant to these commitments the Company was obligated to issue 53,223 common shares valued at $98,900. During the three month period ended March 31, 2016 the 53,223 common shares related to services provided in 2015 were issued. As a result $98,900 recorded as shares to be issued at December 31, 2015 was reclassified to additional paid in capital. During the three months ended March 31, 2016, 64,248 common shares were issued related to investor relations and consulting services provided in 2016 valued at $75,600. (xiv) In February 2016, 45,508 common shares were issued as a result of a cashless exercise of 148,787 warrants with an exercise price of $0.80 under the terms of the warrant agreement. The value of the warrants on exercise was attributed to the shares on exercise. As a result $60,966 was reclassified from warrant derivative liability to additional paid in capital.

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	These options at their respective grant dates were valued using the Black-Scholes option pricing model with the following key assumptions: Grant date Expected life Risk Dividend Forfeiture Expected Grant date February 17, 2015 4.50 1.59 % 0 % 0 % 114 % $ 136,613 July 1, 2014 3.90 1.59 % 0 % 0 % 114 % $ 1,259,487 June 20, 2014 6.07 1.59 % 0 % 0 % 114 % $ 118,957 April 11, 2014 4.14 1.59 % 0 % 0 % 114 % $ 230,930 November 24, 2015 6.5 1.59 % 0 % 0 % 114 % $ 694,384 December 14, 2015 6.5 1.59 % 0 % 0 % 114 % $ 1,260,437 April 21, 2016 0.59 – 9.51 1.59 % 0 % 0 % 114 % $ 2,582,890 April 26, 2016 6.9 1.59 % 0 % 0 % 114 % $ 213,750	Grant date Expected life Risk Dividend Forfeiture Expected Grant date February 17, 2015 5 1.59 % 0 % 0 % 114 % $ 136,613 July 1, 2014 4.35 1.59 % 0 % 0 % 114 % $ 1,259,487 June 20, 2014 6.32 1.59 % 0 % 0 % 114 % $ 118,957 April 11, 2014 4.14 1.59 % 0 % 0 % 114 % $ 230,930 November 24, 2015 7 1.59 % 0 % 0 % 114 % $ 694,384 December 14, 2015 7 1.59 % 0 % 0 % 114 % $ 1,260,437
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the Company’s outstanding options is as follows: Number of Options Weighted-Average Outstanding, December 31, 2015 6,960,609 0.59 Cancelled (355,729) 0.97 Outstanding, March 31, 2016 6,604,880 0.57 Issued 3,250,000 0.77 Cancelled (123,895) 0.45 Outstanding, June 30, 2016 9,730,985 0.64	A summary of the Company’s outstanding options is as follows: Number of Options Weighted-Average Outstanding, December 31, 2013 1,310,665 0.19 Exercised (1,310,665) 0.19 Issued 3,894,252 0.22 Cancelled (125,824) 0.17 Outstanding, December 31, 2014 3,768,428 0.22 Cancelled as a result of Merger (3,768,428) 0.22 Re-issued as part of Merger 3,768,428 0.22 Issued 314,560 0.23 Outstanding March 31, 2015 4,082,988 0.22 Issued 3,145,000 1.05 Cancelled (267,379) 0.22 Outstanding, December 31, 2015 6,960,609 0.59 Cancelled (355,729) 0.97 Outstanding, March 31, 2016 6,604,880 0.57
Share-based Compensation, Performance Shares Award Outstanding Activity [Table Text Block]	The following is a summary of stock options outstanding and exercisable as of June 30, 2016: Exercise Price ($) Number of Options Expiry Date Number of 0.165 374,324 April 1, 2021 374,324 0.23 99,610 June 20, 2021 99,610 0.23 2,972,592 July 1, 2021 2,972,592 0.23 204,460 February 17, 2022 136,314 1.22 400,000 November 24, 2022 - 1.00 2,430,000 December 14, 2022 - 1.00 250,000 April 26, 2023 - 0.25 906,077 July 28, 2025 906,077 0.25 93,923 December 30, 2025 59,158 0.95 9,486 February 2, 2017 9,486 0.95 111,937 March 28, 2023 111,937 0.95 31,620 March 3, 2024 31,620 0.95 15,810 March 14, 2024 15,810 0.95 82,213 September 30, 2024 82,213 0.95 7,431 June 2, 2025 7,431 0.95 671,859 July 29, 2025 671,859 0.95 69,643 December 30, 2025 8,193 1.05 36,697 February 2, 2017 36,697 1.05 423,642 March 28, 2023 423,642 1.05 122,324 March 3, 2024 122,324 1.05 70,548 March 14, 2024 61,162 1.05 318,042 September 30, 2024 318,042 1.05 28,747 June 2, 2025 28,747 9,730,985 6,477,238	The following is a summary of stock options outstanding and exercisable as of March 31, 2016: Exercise Price ($) Number of Options Expiry Date Number of 0.165 437,236 April 1, 2021 291,492 0.23 99,610 June 20, 2021 67,107 0.23 2,972,592 July 1, 2021 2,972,592 0.23 225,442 February 17, 2022 157,285 1.22 400,000 November 24, 2022 - 1.00 2,470,000 December 14, 2022 - 6,604,880 3,488,476

WARRANTS (Tables)

WARRANTS (Tables)	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
Warrants and Rights Note Disclosure [Abstract]
Schedule Of Share Based Compensation Stock Purchase Warrants Activity [Table Text Block]	The following is a continuity schedule of the Company’s common share purchase warrants: Number of Warrants Weighted-Average Outstanding and exercisable, March 31, 2015 10,823,450 1.35 Issued 7,225,625 1.35 Outstanding and exercisable, December 31, 2015 18,049,075 1.35 Exercised (148,787) (0.80) Outstanding and exercisable, March 31, 2016 17,900,288 1.35 Exercised (262,045) (0.80) Outstanding and exercisable, June 30, 2016 17,638,243 1.36	The following is a continuity schedule of the Company’s common share purchase warrants: Number of Warrants Weighted-Average Outstanding and exercisable, December 31, 2014 - - Issued 10,823,450 1.35 Outstanding and exercisable, March 31, 2015 10,823,450 1.35 Issued 7,225,625 1.35 Outstanding and exercisable, December 31, 2015 18,049,075 1.35 Issued 18,049,075 1.35 Exercised (148,787) (0.80) Outstanding and exercisable, March 31, 2016 17,900,288 1.35
Schedule of Common Share Purchase Warrants Outstanding [Table Text Block]	The following is a summary of common share purchase warrants outstanding as of June 30, 2016: Exercise Number of Expiry Date 1.40 7,735,750 February 26, 2019 1.40 1,212,500 March 27, 2019 1.40 891,250 March 31, 2019 1.40 Note 9(i) 3,115,000 April 21, 2019 1.40 Note 9 (ii) 1,418,750 May 27, 2019 1.40 Note 9(iii) 2,035,000 June 30, 2019 0.80 Note (9 i to iii) 1,229,993 February 26, 2019 17,638,243	The following is a summary of common share purchase warrants outstanding as of March 31, 2016: Exercise Number of Expiry Date 1.40 Note 8(vi) 7,735,750 February 26, 2019 0.80 Note 8(vi) 773,575 February 26, 2019 1.40 Note 8(viii) 1,212,500 March 27, 2019 0.80 Note 8(viii) 121,250 February 26, 2019 1.40 Note 8(ix) 891,250 March 31, 2019 0.80 Note 8(ix) 89,125 February 26, 2019 1.40 Note 8(x) 3,115,000 April 21, 2019 0.80 Note 8(x) 311,500 February 26, 2019 1.40 Note 8(xi) 1,418,750 May 27, 2019 0.80 Note 8(xi) 141,875 February 26, 2019 1.40 Note 8(xii) 2,035,000 June 30, 2019 0.80 Note 8(xii) 54,713 February 26, 2019 17,900,288
Schedule Of Warrant derivative liability [Table Text Block]	The following summarizes the changes in the value of the warrant derivative liability from inception until June 30, 2016: Number Value ($) Balance at March 31, 2015 10,823,450 8,382,648 Warrants issued in April 21, 2015 financing 3,426,500 2,588,722 Warrants issued in May 27, 2015 financing 1,560,625 1,025,173 Warrants issued in June 30, 2015 financing 2,238,500 1,490,969 Change in fair value of warrant derivative liability - (7,419,643) Balance at December 31, 2015 18,049,075 6,067,869 Fair value of warrants exercised (148,787) (60,966) Change in fair value of warrant derivative liability - (870,913) Balance at March 31, 2016 17,900,288 5,135,990 Change in fair value of warrant derivative liability - 434,621 Fair value of warrants exercised (262,045) (43,562) Balance at June 30, 2016 17,638,243 5,527,049	The following summarizes the changes in the value of the warrant derivative liability from inception until March 31, 2016: Number Value ($) Warrants issued in February 26, 2015 financing Note 8(vi) 8,509,325 550,374 Warrants issued in March 27, 2015 financing Note 8(viii) 1,333,750 1,036,325 Warrants issued in March 31, 2015 financing Note 8(ix) 980,375 759,290 Change in fair value of warrant derivative liability 6,036,659 Balance at March 31, 2015 8,382,648 Warrants issued in April 21, 2015 financing Note 8(x) 3,426,500 2,588,722 Warrants issued in May 27, 2015 financing Note 8(xi) 1,560,625 1,025,173 Warrants issued in June 30, 2015 financing Note 8(xii) 2,238,500 1,490,969 Change in fair value of warrant derivative liability (7,419,643) Balance at December 31, 2015 6,067,869 Fair value of warrants exercised (60,966) Change in fair value of warrant derivative liability (870,913) Balance at March 31, 2016 5,135,990
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	The key inputs and assumptions used in the simulation model at inception and at June 30, 3016 and March 31, 2016 are as follows: Grant date Number of Expected Exercise Risk Dividend Expected Fair At Inception: February 26, 2015 7,735,750 4 1.4 0.44 % 0 % 51.83 % 464,784 February 26, 2015 773,575 4 0.8 0.44 % 0 % 51.83 % 85,590 March 27, 2015 1,212,500 3.92 1.4 0.43 % 0 % 52.37 % 950,913 March 27, 2015 121,250 3.92 0.8 0.43 % 0 % 52.37 % 85,412 March 31, 2015 891,250 3.91 1.4 0.41 % 0 % 52.45 % 696,582 March 31, 2015 89,125 3.91 0.8 0.41 % 0 % 52.45 % 62,708 April 21, 2015 3,115,000 3.85 1.4 0.68 % 0 % 51.54 % 2,371,956 April 21, 2015 311,500 3.85 0.8 0.68 % 0 % 51.54 % 216,766 May 27, 2015 1,418,750 3.76 1.4 0.46 % 0 % 51.74 % 933,065 May 27, 2015 141,875 3.76 0.8 0.46 % 0 % 51.74 % 92,108 June 30, 2015 2,035,000 3.66 1.4 0.37 % 0 % 52.94 % 1,356,512 June 30, 2015 203,500 3.66 0.8 0.37 % 0 % 52.94 % 134,457 At year end March 31, 2016: March 31, 2016 16,408,250 2.91 1.4 0.21 % 0 % 62.96 % 4,585,539 March 31, 2016 1,492,038 2.91 0.8 0.21 % 0 % 62.96 % 550,451 At Period End: June 30, 2016 16,408,250 2.66 1.4 0.26 % 0 % 70.77 % 5,003,830 June 30, 2016 1,229,993 2.66 0.8 0.26 % 0 % 70.77 % 523,219	The key inputs and assumptions used in the simulation model at inception and at March 31, 2016 and 2015 and December 31, 2015 are as follows: Grant date Number of Expected Exercise Risk Dividend Expected Fair At Inception: February 26, 2015 7,735,750 4 1.4 0.44 % 0 % 51.83 % 464,784 February 26, 2015 773,575 4 0.8 0.44 % 0 % 51.83 % 85,590 March 27, 2015 1,212,500 3.92 1.4 0.43 % 0 % 52.37 % 950,913 March 27, 2015 121,250 3.92 0.8 0.43 % 0 % 52.37 % 85,412 March 31, 2015 891,250 3.91 1.4 0.41 % 0 % 52.45 % 696,582 March 31, 2015 89,125 3.91 0.8 0.41 % 0 % 52.45 % 62,708 April 21, 2015 3,115,000 3.85 1.4 0.68 % 0 % 51.54 % 2,371,956 April 21, 2015 311,500 3.85 0.8 0.68 % 0 % 51.54 % 216,766 May 27, 2015 1,418,750 3.76 1.4 0.46 % 0 % 51.74 % 933,065 May 27, 2015 141,875 3.76 0.8 0.46 % 0 % 51.74 % 92,108 June 30, 2015 2,035,000 3.66 1.4 0.37 % 0 % 52.94 % 1,356,512 June 30, 2015 203,500 3.66 0.8 0.37 % 0 % 52.94 % 134,457 At Period End: March 31, 2016 16,408,250 2.91 1.4 0.21 % 0 % 62.96 % 4,585,539 March 31, 2016 1,492,038 2.91 0.8 0.21 % 0 % 62.96 % 550,451 At Period End: December 31, 2015 16,408,250 3.16 1.4 0.65 % 0 % 53.58 % 5,315,536 December 31, 2015 1,640,825 3.16 0.8 0.65 % 0 % 53.58 % 752,333 At Period End: March 31, 2015 9,839,500 3.91 1.4 0.41 % 0 % 52.45 % 7,690,340 March 31, 2015 983,950 3.91 0.8 0.41 % 0 % 52.45 % 692,308

INCOME TAXES (Tables)

INCOME TAXES (Tables)	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Components of net (loss) income before income taxes consists of the following: 3 months Year Year ended Nine $ $ $ $ U.S. 183,461 4,706,413 (2,372,510) - Canada (1,187,553) (3,670,265) (3,221,396) (2,464,747) (1,004,092) 1,036,148 (5,593,906) (2,464,747) Reconciliation of the statutory tax rate of 35 26.5 3 months Year ended Year ended Nine $ $ $ $ Net (loss) income for the period before recovery of income taxes (1,004,092) 1,036,148 (5,593,906) (2,464,747) Statutory rate 35 % 35 % 35 % 26.5 % Expected income tax (recovery) expense (351,432) 362,652 (1,957,867) (653,158) Tax rate changes and other basis adjustments (162,267) 195,108 364,651 (29,109) Change in fair value of derivative liability (304,835) (2,709,894) (169,443) Stock-based compensation 55,350 512,693 587,381 - Non-deductible expenses (99,642) (12,073) 227,068 193,305 Change in valuation allowance 862,826 1,651,514 948,210 488,962 Recovery of income taxes - - - -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Deferred tax reflects the tax effects of temporary differences that gave rise to significant portions of deferred tax assets and liabilities and consisted of the following: March 31, March 31, December 31, December 31, $ $ $ $ Property and equipment 52,331 34,556 47,495 36,940 Share issue costs 3,586 5,838 3,877 162,350 SR&ED pool 400,557 103,799 340,585 7,137 Other 215,202 32,447 39,947 18,621 Non-capital losses – Canada 1,587,439 977,178 1,149,389 812,522 Net operating losses - U.S. 589,491 43,274 404,487 - Valuation allowance (2,848,606) (1,197,092) (1,985,780) (1,037,570) - - - -
Summary of Income Tax Examinations [Table Text Block]	In many cases the Company’s uncertain tax positions are related to tax years that remain subject to examination by tax authorities. The following describes the open tax years, by major tax jurisdiction, as of March 31, 2016: United States - Federal 2013 – present United States – State 2013 – present Canada – Federal 2012 - present Canada – Provincial 2012 - present

(LOSS) PER SHARE (Tables)

(LOSS) PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]	The reconciliation of diluted (loss) per share for the year ended March 31, 2016 is presented below: Numerator Net income $ 1,036,148 Change in fair value of warrant derivative liability (7,742,555) Net (loss) used in computation of diluted EPS $ (6,706,407) Denominator Basic weighted average number of shares outstanding 71,554,822 Warrants 8,429,435 Diluted weighted average number of shares outstanding 79,984,257 Diluted loss per share $ (0.08)

TRANSITION PERIOD COMPARATIVE38

TRANSITION PERIOD COMPARATIVE DATA (Tables)	3 Months Ended
	Mar. 31, 2016
Transition Period Comparative Data [Abstract]
Transition Period Comparative Data [Table Text Block]	Three months March 31, 2015 $ Operating Data: Expenses Research and development 435,671 Professional and consulting fees 261,350 General and administrative 167,747 Depreciation 10,412 Share-based compensation expense 371,637 1,246,817 Other expenses (income) Interest expense 179 Other income (323) Change in fair value of warrant derivative liability 6,387,473 Total other expense (income) 6,387,329 Net loss for the period (7,634,146) Foreign exchange translation adjustment for the period 24,799 Net loss and comprehensive loss for the period (7,609,347) Loss per share - basic and diluted (0.14) Weighted average number of shares outstanding – basic and diluted 52,726,746 Cash flow Data: Net cash used in operating activities (825,483) Net cash used in investing activities (38,820) Net cash provided by financing activities 6,788,988 Effects of foreign currency exchange rate changes (9,510) Net increase in cash and cash equivalents for the period 5,915,175

SUBSEQUENT EVENTS (Tables)

SUBSEQUENT EVENTS (Tables)	3 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
Summary of Consideration Transferred And Purchase Price Allocation [Table Text Block]	As at April 21, 2016 $ Consideration Paid: Fair value of 23,650,000 common shares 23,177,000 Fair value of vested stock options 1,573,229 24,750,229 Allocation of purchase price: Net assets acquired (2,129,089) Intangible assets and goodwill 26,879,318 24,750,229
Business Acquisition Sales and Net Loss Pro Forma [Table Text Block]	The unaudited pro forma sales and net loss for the period indicated are as follows: Year Ended $ Sales 1,919,779 Net loss for the period (15,550,891)

NATURE OF OPERATIONS (Details T

NATURE OF OPERATIONS (Details Textual)	1 Months Ended		3 Months Ended				9 Months Ended			12 Months Ended
	Apr. 21, 2016shares	Feb. 26, 2015shares	Jun. 30, 2016USD ($)shares	Mar. 31, 2016USD ($)shares	Jun. 30, 2015USD ($)	Mar. 31, 2015USD ($)shares	Mar. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)shares	Mar. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)shares	Mar. 31, 2015USD ($)shares	Mar. 31, 2014USD ($)	Dec. 31, 2013shares
Working Capital Surplus (Deficit)			$ 3,704,539	$ 187,156		$ (2,599,374)	$ 187,156	$ 890,885	$ (128,361)	$ 187,156	$ 890,885	$ (2,599,374)
Stockholders' Equity Attributable to Parent			23,963,904	263,906	$ (2,702,805)	(2,498,745)	$ 263,906	$ 977,988	(50,439)	263,906	977,988	(2,498,745)	$ (774,626)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent			$ (2,322,772)	$ (1,004,092)	(1,501,618)	$ (7,609,347)			$ (2,489,137)	$ 1,036,148	$ (5,569,107)	$ (10,098,484)
Stockholders' Equity, Reverse Stock Split			1-for-0.831105						1-for-0.831105
Common Stock, Shares Authorized | shares			150,000,000	150,000,000		150,000,000	150,000,000	150,000,000	200,000,000	150,000,000	150,000,000	150,000,000		200,000,000
Net Income (Loss) Attributable to Parent			$ (2,322,772)	$ (1,004,092)	(1,501,618)	$ (7,634,146)	$ 2,537,766	$ 2,040,240	$ (2,464,747)	$ 1,036,148	$ (5,593,906)	$ (10,098,893)
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | shares			23,650,000
Retained Earnings (Accumulated Deficit)			$ (13,974,752)	(11,651,980)		(12,688,128)	(11,651,980)	(10,647,888)	(5,053,982)	(11,651,980)	(10,647,888)	(12,688,128)
Cash and Cash Equivalents, at Carrying Value			2,749,953	$ 5,381,757	$ 9,078,216	$ 6,125,108	$ 5,381,757	$ 6,617,082	$ 209,933	$ 5,381,757	$ 6,617,082	$ 6,125,108	$ 3,482
Business Acquisition, Transaction Costs			$ 931,103
Interactive Motion Technologies Inc [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | shares	23,650,000
Share Exchange Agreement [Member]
Stock Issued During Period, Shares, New Issues | shares		50,000,000
Debt Instrument, Convertible, Conversion Ratio		3.14
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage		100.00%

SIGNIFICANT ACCOUNTING POLICI41

SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($)	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
Significant Accounting Policies [Line Items]
Standard and Extended Product Warranty Accrual	$ 61,380
Product Warranty Expense	$ 15,190
Computer And Electronics [Member]
Significant Accounting Policies [Line Items]
Percentage Of Depreciated Per Annum		50.00%
Furniture and Fixtures [Member]
Significant Accounting Policies [Line Items]
Percentage Of Depreciated Per Annum		20.00%
Tool and Parts [Member]
Significant Accounting Policies [Line Items]
Percentage Of Depreciated Per Annum		20.00%

ACQUISITION (Details)

ACQUISITION (Details)	1 Months Ended
	Apr. 21, 2016USD ($)
Consideration Paid:
Fair value of 23,650,000 common shares	$ 23,177,000	[1]
Fair value of vested stock options	2,582,890	[2]
Total Consideration Paid	25,759,890
Allocation of purchase price:
Cash and cash equivalents	266,635
Accounts receivable	6,490
Inventories	188,879
Prepaid expenses and other current assets	16,839
Equipment	59,749
Liabilities assumed:
Accounts payable	(241,299)
Accrued liabilities	(361,029)
Customer deposits	(86,487)
Demand notes payable	(324,894)
Promissory notes payable	(217,808)
Bionik advance	(1,436,164)
Net assets acquired	(2,129,089)
Intangible assets and goodwill	27,888,979
Total Allocation of purchase price	$ 25,759,890
[1]	The fair value of common shares is based on $0.98 the closing market price of the Company’s shares on April 21, 2016.
[2]	The fair value of the vested stock options was determined using the Black Scholes option pricing model with the following key assumptions: a risk free rate of 1.59%, dividend and forfeiture rates of 0% and expected volatility of 114% which is consistent with the Company’s assumptions (Note 10)

ACQUISITION (Details1)

ACQUISITION (Details1)	2 Months Ended
	Jun. 30, 2016USD ($)
Business Acquisition [Line Items]
Revenue	$ 162,588
Net loss and comprehensive loss	$ (292,634)

ACQUISITION (Details2)

ACQUISITION (Details2) - USD ($)	3 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Business Acquisition [Line Items]
Revenue	$ 166,028	$ 438,414
Net loss and comprehensive loss	$ (407,245)	$ (124,548)

ACQUISITION (Details Textual)

ACQUISITION (Details Textual) - USD ($)	1 Months Ended		3 Months Ended
	Jul. 31, 2016	Apr. 21, 2016	Jun. 30, 2016
Business Acquisition [Line Items]
Fair Value Assumption Forfeited Rate		0.00%
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares			23,650,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		3,000,000
Fair Value Assumptions, Risk Free Interest Rate		1.59%
Fair Value Assumptions, Expected Volatility Rate		114.00%
Subsequent Event [Member]
Business Acquisition [Line Items]
Stock Issued During Period, Shares, Acquisitions	11,310,157
Common Stock [Member]
Business Acquisition [Line Items]
Stock Issued During Period, Shares, Acquisitions			12,339,843
Exercise Price 0.25 [Member]
Business Acquisition [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price		$ 0.25
Exercise Price 0.95 [Member]
Business Acquisition [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price		$ 0.95
Exercise Price 1.05 [Member]
Business Acquisition [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price		$ 1.05
Interactive Motion Technologies Inc [Member]
Business Acquisition [Line Items]
Business Acquisition Number Of Option Acquired		3,895,000
Business Acquisition, Percentage of Voting Interests Acquired		100.00%
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		23,650,000
Allocated Share-based Compensation Expense		$ 2,582,890
Share Price		$ 0.98
Business Acquisition, Effective Date of Acquisition		Apr. 21, 2016
Interactive Motion Technologies Inc [Member] | Subsequent Event [Member]
Business Acquisition [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		23,650,000

PREPAID EXPENSES AND OTHER RE46

PREPAID EXPENSES AND OTHER RECEIVABLES (Details) - USD ($)		Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Prepaid Expense And Other Receivables [Line Items]
Prepaid expenses and other receivables		$ 75,831	$ 87,979	$ 120,661	$ 6,242	$ 18,172
Prepaid insurance		83,329	107,259	12,966	126,771	40,630
Sales taxes receivable	[1]	29,270	36,495	54,590	25,406	22,328
Prepaid Expense and Other Assets		$ 188,430	$ 231,733	$ 188,217	$ 158,419	$ 81,130
[1]	Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORIES (Details)

INVENTORIES (Details) - USD ($)	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Inventory [Line Items]
Raw Materials	$ 218,047	$ 0
Work in Progress	42,212	0
Inventory, Net	$ 260,259	$ 0

EQUIPMENT (Details)

EQUIPMENT (Details) - USD ($)	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Cost	$ 424,312	$ 186,164	$ 183,132	$ 143,301	$ 114,472
Accumulated Depreciation	297,976	109,414	96,029	42,672	36,550
Property, Plant and Equipment, Net	126,336	76,750	87,103	100,629	77,922
Computers and electronics [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Cost	262,853	152,246	148,214	107,369	77,650
Accumulated Depreciation	184,636	96,379	84,072	33,933	27,438
Property, Plant and Equipment, Net	78,217	55,867	64,142	73,436	50,212
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Cost	36,795	22,496	23,496	23,832	24,909
Accumulated Depreciation	24,361	10,118	9,478	7,689	7,325
Property, Plant and Equipment, Net	12,434	12,378	14,018	16,143	17,584
Demonstration Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Cost	28,800	0
Accumulated Depreciation	1,200	0
Property, Plant and Equipment, Net	27,600	0
Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Cost	84,442	0
Accumulated Depreciation	84,442	0
Property, Plant and Equipment, Net	0	0
Tools and Parts [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Cost	11,422	11,422	11,422	12,100	11,913
Accumulated Depreciation	3,337	2,917	2,479	1,050	1,787
Property, Plant and Equipment, Net	$ 8,085	$ 8,505	$ 8,943	$ 11,050	$ 10,126

EQUIPMENT (Details Textual)

EQUIPMENT (Details Textual) - USD ($)	3 Months Ended				9 Months Ended	12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015
Property, Plant and Equipment [Line Items]
Depreciation	$ 10,163	$ 14,387	$ 17,002	$ 10,412	$ 34,036	$ 63,454	$ 59,479	$ 44,448
Capital Leases, Balance Sheet, Assets by Major Class, Net	23,019
Capital Lease Obligations, Current	4,603	0				0
Capital Lease Obligations, Noncurrent	$ 18,032	$ 0				$ 0

NOTES PAYABLE (Details Textual)

NOTES PAYABLE (Details Textual) - USD ($)	1 Months Ended		3 Months Ended
	Mar. 01, 2016	Dec. 14, 2015	Jun. 30, 2016	Feb. 28, 2014
IMT Notes [Member]
Debt Instrument [Line Items]
Debt Instrument Demand Deferral Minimum Capital Proceeds Required	$ 15,000,000
Notes Payable			$ 328,840
Debt Instrument, Interest Rate, Stated Percentage	3.50%
Interest Expense, Debt			3,325
IMT Notes [Member] | Director [Member]
Debt Instrument [Line Items]
Notes Payable			148,974
Promissory Note [Member]
Debt Instrument [Line Items]
Notes Payable				$ 200,000
Debt Instrument, Interest Rate, Stated Percentage				10.00%
Interest Expense, Debt			$ 3,890
Promissory Note [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Debt Instrument Amended Maturity Year Month		2017-03

LOANS RECEIVABLE AND SHORT TE51

LOANS RECEIVABLE AND SHORT TERM ADVANCES (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2016	Jun. 30, 2016	Apr. 21, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Interest Receivable, Current					$ 0	$ 0
Loans Receivable, Net, Total	$ 379,908	$ 0		$ 307,459	0	0
Other Receivables, Net, Current, Total	125,153	$ 0		0	0	0
Interactive Motion Technologies Inc [Member]
Loans and Leases Receivable, Related Parties				$ 300,000
Debt Instrument, Interest Rate, Stated Percentage				6.00%
Interest Payable, Current					$ 0	$ 0
Interest Receivable, Current	11,158			$ 7,459
Subordinated Debt				$ 200,000
Other Receivables, Net, Current, Total	125,153		$ 125,153
Loans and Leases Receivable, Related Parties, Additions	$ 68,750
Interactive Motion Technologies Inc [Member] | Subsequent Event [Member]
Loans Receivable, Net, Total			$ 379,908

CONVERTIBLE SECURED PROMISSORY

CONVERTIBLE SECURED PROMISSORY NOTE (Details Textual)	May 09, 2014$ / shares	Dec. 08, 2011CAD	Feb. 28, 2014USD ($)	Feb. 28, 2012CAD	Jun. 30, 2016	Mar. 31, 2016USD ($)	Dec. 31, 2014USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Mar. 31, 2015USD ($)	May 09, 2014CAD / shares
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate					1.00%
Imputed Interest Expense | $						$ 0	$ 27,677	$ 0	$ 0	$ 27,677
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Proceeds from Issuance of Debt | CAD		CAD 61,500
Proceeds From Issuance Of Additional Debt | CAD				CAD 60,000
Debt Instrument, Face Amount | CAD				CAD 121,500
Debt Instrument, Description			convert the principal plus accrued interest at a discount of 20% to the share price in the event of a qualifying financing
Debt Instrument, Convertible, Beneficial Conversion Feature | $			$ 27,677
Debt Instrument, Basis Spread on Variable Rate			1.00%
Fair Value Inputs, Discount Rate	20.00%
Debt Instrument, Convertible, Conversion Price | (per share)	$ 0.22										CAD 0.24
Imputed Interest Expense | $			$ 27,677

RELATED PARTY TRANSACTIONS AN53

RELATED PARTY TRANSACTIONS AND BALANCES (Details Textual)	3 Months Ended			9 Months Ended		12 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2016CAD	Mar. 31, 2016USD ($)	Dec. 31, 2014USD ($)shares	Dec. 31, 2014CADshares	Mar. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Mar. 31, 2015USD ($)
Related Party Transaction [Line Items]
Due from Related Parties	$ 41,623		$ 41,445	$ 44,986		$ 41,445	$ 38,554	$ 41,480
Debt Instrument, Basis Spread on Variable Rate	1.00%	1.00%
Repayments of Other Debt	$ 37,837	CAD 44,000
Accrued interest receivable	392		$ 392			1,148	756
Convertible Secured Promissory Note [Member]
Related Party Transaction [Line Items]
Debt Instrument, Basis Spread on Variable Rate			1.00%
Director [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Amounts of Transaction				$ 85,947	CAD 95,000
Stock Issued During Period, Shares, Issued for Services | shares				331,443	331,443
Chief Operating Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	16,941		$ 8,812	$ 0		8,812	878	7,025
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	1,118		2,694	4,220		2,694	2,970	1,490
Chief Technology Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	0		3,284	5,930		3,284	856	9,752
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	0		$ 116	$ 0		$ 116	$ 346	$ 0
Vp Us Operations [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	$ 102

SHARE CAPITAL (Details)

SHARE CAPITAL (Details) - USD ($)		1 Months Ended		3 Months Ended							9 Months Ended					12 Months Ended
		Mar. 01, 2016	Feb. 29, 2016	Jun. 30, 2016		Mar. 31, 2016		Jun. 30, 2015	Mar. 31, 2015		Mar. 31, 2016	Dec. 31, 2015		Dec. 31, 2014		Dec. 31, 2015
Opening Balance				$ 263,906		$ 977,988		$ (2,498,745)	$ (50,439)		$ (2,702,805)	$ (2,498,745)		$ (774,626)		$ (50,439)
Shares issued on acquisition (Note 3)				23,177,000
Shares issued as Merger consideration									0
Shares issued under private placement								0	4,789,404			0
Shares issued for services				$ 59,500		70,800					169,700	98,900
Shares issued on exercise of stock options														228,875
Cashless exercise of warrants (in shares)		45,508	45,508	51,249
Cashless exercise of warrants				$ 43,562		60,966					60,966
Closing Balance				$ 23,963,904		$ 263,906		$ (2,702,805)	$ (2,498,745)		$ 263,906	$ 977,988		$ (50,439)		$ 977,988
Number Of Warrants Exercised		148,787	148,787	(262,045)		(148,787)
Exchangable Shares [Member]
Opening Balance (in shares)				50,000,000		50,000,000		50,000,000	49,737,096			50,000,000		36,621,885		49,737,096
Opening Balance				$ 50,000		$ 50,000		$ 50,000	$ 49,737			$ 50,000		$ 36,622		$ 49,737
Shares issued under private placement (in shares)	[1]								0					10,792,335
Shares issued under private placement	[1]								$ 0					$ 10,792
Shares issued on conversion and settlement of debt (in shares)	[2],[3]								0					1,012,142
Shares issued on conversion and settlement of debt	[2],[3]								$ 0					$ 1,012
Shares issued for services (in shares)	[4]								262,904					0
Shares issued for services	[4]								$ 263					$ 0
Shares issued on exercise of stock options (in shares)	[5]								0					1,310,734
Shares issued on exercise of stock options	[5]								$ 0					$ 1,311
Closing Balance (in shares)						50,000,000			50,000,000		50,000,000	50,000,000		49,737,096		50,000,000
Closing Balance						$ 50,000			$ 50,000		$ 50,000	$ 50,000		$ 49,737		$ 50,000
Common Shares [Member]
Opening Balance (in shares)				22,591,292		22,428,313		15,839,563	0			15,839,563		0		0
Opening Balance				$ 22,591		$ 22,428		$ 15,840	$ 0			$ 15,840		$ 0		$ 0
Shares issued on acquisition (Note 3) (in shares)				12,339,843
Shares issued on acquisition (Note 3)				$ 12,339
Shares issued as Merger consideration (in shares)	[6]								6,000,063					0
Shares issued as Merger consideration	[6]								$ 6,000					$ 0
Shares issued under private placement (in shares)						0			9,839,500	[7],[8],[9]		6,568,750	[10],[11],[12]	0	[7],[8],[9]
Shares issued under private placement						$ 0			$ 9,840	[7],[8],[9]		$ 6,568	[10],[11],[12]	$ 0	[7],[8],[9]
Shares issued for services (in shares)				70,000	[13]	117,471	[14]					20,000	[14]
Shares issued for services				$ 70	[13]	$ 117	[14]					$ 20	[14]
Cashless exercise of warrants (in shares)				51,249	[15]	45,508	[16]					0
Cashless exercise of warrants				$ 51	[15]	$ 46	[16]					$ 0
Closing Balance (in shares)				35,052,384		22,591,292			15,839,563		22,591,292	22,428,313		0		22,428,313
Closing Balance				$ 35,051		$ 22,591			$ 15,840		$ 22,591	$ 22,428		$ 0		$ 22,428
Common Shares And Exchangeable Shares [Member]
Opening Balance (in shares)				72,591,292		72,428,313		65,839,563	0			65,839,563				0
Opening Balance				$ 72,591		$ 72,428		$ 65,840	$ 0			$ 65,840				$ 0
Closing Balance (in shares)				85,052,384		72,591,292			65,839,563		72,591,292	72,428,313		0		72,428,313
Closing Balance				$ 85,052		$ 72,591			$ 65,840		$ 72,591	$ 72,428		$ 0		$ 72,428
[1]	In April, 2014, the Company completed a private placement issuing 10,792,335 common shares at a price of $0.24 per share for gross proceeds of $2,616,062. A former director of the Company assisted in securing a significant portion of this financing. The Company incurred $11,609 in share issue costs related to the transaction.
[2]	In June, 2014, the Company issued 575,234 common shares on conversion of the convertible secured promissory note (Note 6). The note plus accrued interest totaled $124,523 and was converted at a 20% discount to the April 2014 private placement.
[3]	In May 2014, the Company issued 436,908 common shares in exchange for the settlement of $115,223 of unsecured debt.
[4]	On February 25, 2015, 262,904 common shares were issued to two former lenders connected with a $241,185 loan received and repaid during fiscal 2013. The common shares were valued at $210,323 based on the value of the concurrent private placement (Note 8(vi)), and recorded in stock-based compensation on the consolidated statement of operations and comprehensive loss. As part of the consideration for the initial loan the CTO and COO had transferred 314,560 common shares to the lenders. For contributing the common shares to the lenders, the Company intends to reimburse the CTO and COO 320,000 common shares. As at March 31, 2016, these shares have not yet been issued.
[5]	In June 2014, the Company issued 1,310,734 common shares for the exercise of stock options. The Company received cash of $228,875.
[6]	Immediately following the Merger and the First Closing, 6,000,063 common shares were held by existing Drywave stockholders, 7,735,750 were held by the investors in the Offering and Bionik Canada shareholders held an equivalent of 50,000,000 shares of the common shares through their ownership of 100% of the Exchangeable Shares which are held in 1 Special Preferred Share. The Special Preferred Share votes on behalf of the 50,000,000 Exchangeable Shares alongside the common shares of the Company as a single class.
[7]	Concurrently with the closing of the Merger on February 26, 2015, the Company issued 7,735,750 units (the “Units”) for gross proceeds of $6,188,600 (the “First Closing”) (including $500,000 of outstanding bridge loans converted into Units at the offering price) at a purchase price of $0.80 per Unit (the “Purchase Price”) in a private placement offering (the “Offering”). Each Unit consists of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other costs related to the transaction of $848,822 and issued 773,575 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant derivative liability on the consolidated balance sheet (Note 10). After deducting the value of the warrants and the share issue costs, $4,789,404 was attributed to the value of the common shares.
[8]	On March 27, 2015, the Company issued 1,212,500 Units for gross proceeds of $970,000 to accredited investors in a second closing (the “Second Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other costs related to the Second Closing of $141,100 and issued 121,250 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant liability on the consolidated balance sheet (Note 10). The fair value of the warrants exceeded the net proceeds received upon closing and as a result $207,425 was recorded as a loss on initial recognition of the warrants and included in the change in fair value of warrant derivative liability on the consolidated statements of operations and comprehensive loss.
[9]	On March 31 2015, the Company issued 891,250 Units for gross proceeds of $713,000 to accredited investors in a third closing (the “Third Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other costs related to the Third Closing of $97,099 and issued 89,125 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant liability on the consolidated balance sheet (Note 10). The fair value of the warrants exceeded the net proceeds received upon closing and as a result $143,389 was recorded as a loss on initial recognition of the warrants and included in the change in fair value of warrant derivative liability on the consolidated statements of operations and comprehensive loss.
[10]	On April 21, 2015, the Company issued 3,115,000 Units for gross proceeds of $2,492,000 to accredited investors in a fourth closing (the “Fourth Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other related to the Fourth Closing of $338,960 and issued 311,500 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant liability on the consolidated balance sheet (Note 10). The fair value of the warrants exceeded the net proceeds received upon closing and as a result $435,682 was recorded as a loss on initial recognition of the warrants and included in the change in fair value of warrant derivative liability on the consolidated statements of operations and comprehensive loss.
[11]	On June 30, 2015, the Company issued 2,035,000 Units for gross proceeds of $1,628,000 to accredited investors in a sixth and final closing (the “Sixth Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other costs related to the Sixth Closing of $211,656 and issued 203,500 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant liability on the consolidated balance sheet (Note 10). The fair value of the warrants exceeded the net proceeds received upon closing and as a result $74,625 was recorded as a loss on initial recognition of the warrants and included in the change in fair value of warrant derivative liability on the consolidated statements of operations and comprehensive loss.
[12]	On May 27, 2015, the Company issued 1,418,750 Units for gross proceeds of $1,135,000 to accredited investors in a fifth closing (the “Fifth Closing”). Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years. The Company incurred share issue costs before legal and other costs related to the Fifth Closing of $147,566 and issued 141,875 broker warrants exercisable at $0.80 for a period of 4 years. The warrants were measured at fair value and recorded as a warrant liability on the consolidated balance sheet (Note 10). The fair value of the warrants exceeded the net proceeds received upon closing and as a result $37,739 was recorded as a loss on initial recognition of the warrants and included in the change in fair value of warrant derivative liability on the consolidated statements of operations and comprehensive loss.
[13]	The Company issued 70,000 common shares during the three month period ended June 30, 2016 for consulting services and recognized $59,500 of share compensation expense.
[14]	During the year ended December 31, 2015, the Company entered into service agreements which included paying some of the fees in common shares. During the year ended December 31, 2015, the Company issued 20,000 shares pursuant to these commitments valued at $31,000 and included in share-based compensation. In addition, pursuant to these commitments the Company was obligated to issue 53,223 common shares valued at $98,900. During the three month period ended March 31, 2016 the 53,223 common shares related to services provided in 2015 were issued. As a result $98,900 recorded as shares to be issued at December 31, 2015 was reclassified to additional paid in capital. During the three months ended March 31, 2016, 64,248 common shares were issued related to investor relations and consulting services provided in 2016 valued at $75,600.
[15]	During the three month period ended June 30, 2016, 51,249 common shares were issued as a result of a cashless exercise of 262,045 warrants with an exercise price of $0.80. Under the terms of the warrant agreement the value of the warrants on exercise is attributed to the shares on exercise and the Company has recognized a value of $43,562.
[16]	In February 2016, 45,508 common shares were issued as a result of a cashless exercise of 148,787 warrants with an exercise price of $0.80 under the terms of the warrant agreement. The value of the warrants on exercise was attributed to the shares on exercise. As a result $60,966 was reclassified from warrant derivative liability to additional paid in capital.

SHARE CAPITAL (Details Textual)

SHARE CAPITAL (Details Textual)	1 Months Ended												3 Months Ended				9 Months Ended			12 Months Ended
	Mar. 01, 2016shares	Feb. 29, 2016USD ($)$ / sharesshares	Jun. 30, 2015USD ($)$ / sharesshares	May 27, 2015USD ($)$ / sharesshares	Apr. 21, 2015USD ($)$ / sharesshares	Mar. 31, 2015USD ($)$ / sharesshares	Mar. 27, 2015USD ($)$ / sharesshares	Feb. 26, 2015USD ($)$ / shares$ / Unitshares	Feb. 25, 2015USD ($)shares	Jun. 30, 2014USD ($)shares	May 30, 2014USD ($)shares	Apr. 30, 2014USD ($)$ / sharesshares	Jun. 30, 2016USD ($)$ / sharesshares	Mar. 31, 2016USD ($)shares	Jun. 30, 2015USD ($)$ / sharesshares	Mar. 31, 2015USD ($)$ / sharesshares	Mar. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)$ / shares	Mar. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)shares	Mar. 31, 2015USD ($)$ / sharesshares
Stock Issued During Period, Value, Stock Options Exercised																			$ 228,875
Stock Issued During Period, Value, Issued for Services													$ 59,500	$ 70,800			$ 169,700	$ 98,900
Share-based Compensation													$ 219,248	$ 158,244	$ 1,297,558	$ 371,637			112,573	$ 1,495,837	$ 1,709,230	$ 484,210
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 0.80
Class of Warrant or Right, Outstanding | shares						10,823,450							17,638,243	17,900,288		10,823,450	17,900,288	18,049,075		17,900,288	18,049,075	10,823,450
Fair Value Adjustment of Warrants													$ 391,059	$ (870,913)	$ (917,749)	$ 6,387,473	$ (7,419,643)	$ (7,419,643)	$ 0	$ (7,742,555)	$ (484,124)	$ 6,387,473
Reclassification Of Warrants Liability To Additional Paid In Capital		$ 60,966
Stock Issued During Period, Shares, Upon Cashless Exercise Of Warrants | shares	45,508	45,508											51,249
Number Of Warrants Exercised | shares	148,787	148,787											(262,045)	(148,787)
Service Agreements [Member]
Stock Issued During Period, Shares, Issued for Services | shares														53,223							20,000
Stock Issued During Period, Value, Issued for Services														$ 98,900							$ 31,000
Investor Relation And Consultine Services [Member]
Stock Issued During Period, Shares, Issued for Services | shares														64,248
Stock Issued During Period, Value, Issued for Services														$ 75,600
Warrant Agreement [Member]
Stock Issued During Period, Shares, Upon Cashless Exercise Of Warrants | shares		45,508
Number Of Warrants Exercised | shares		148,787
Unsecured Debt [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares											436,908
Debt Conversion, Converted Instrument, Amount											$ 115,223
Investor [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																			$ 0.23
Exchangable Shares [Member]
Stock Issued During Period, Shares, Other | shares												10,792,335
Shares Issued, Price Per Share | $ / shares												$ 0.24
Proceeds from Issuance of Private Placement												$ 2,616,062
Payments of Stock Issuance Costs												$ 11,609
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares										1,310,734
Stock Issued During Period, Value, Stock Options Exercised										$ 228,875
Stock Transferred To Lenders | shares									314,560
Stock Reimbursed To Officers | shares									320,000
Stock Issued During Period, Shares, Issued for Services | shares									262,904				70,000
Stock Issued During Period, Value, Issued for Services									$ 241,185				$ 59,500
Share-based Compensation									$ 210,323				$ 43,562
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares													$ 0.80
Stock Issued During Period, Shares, Acquisitions | shares								50,000,000
Stock Issued During Period, Shares, Upon Cashless Exercise Of Warrants | shares													51,249
Number Of Warrants Exercised | shares													262,045
First Closing [Member]
Payments of Stock Issuance Costs								$ 848,822
Stock Units Issued During Period | shares								7,735,750
Proceeds From Issuance of Stock Units								$ 6,188,600
Stock Units Issued During Period, Purchase Price Per Unit | $ / Unit								0.80
Warrants Exercisable Period								4 years
Bridge Loan								$ 500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares								$ 1.40
Class of Warrant or Right, Outstanding | shares								773,575
Stock Issued During Period, Shares, Acquisitions | shares								50,000,000
Business Acquisition, Percentage of Voting Interests Acquired								0.00%
Warrants Exercisable Price Per Warrants | $ / shares								$ 0.80
Net proceeds after share issue costs and warrant liability set-up								$ 4,789,404
First Closing [Member] | Investor [Member]
Stock Issued During Period, Shares, Acquisitions | shares								7,735,750
First Closing [Member] | Drywave Stockholders [Member]
Stock Issued During Period, Shares, Acquisitions | shares								6,000,063
Second Closing [Member]
Payments of Stock Issuance Costs							$ 141,100
Stock Units Issued During Period | shares							1,212,500
Proceeds From Issuance of Stock Units							$ 970,000
Stock Units Description							Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years
Warrants Exercisable Period							4 years
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares							$ 1.40
Class of Warrant or Right, Outstanding | shares							121,250
Fair Value Adjustment of Warrants							$ 207,425
Warrants Exercisable Price Per Warrants | $ / shares							$ 0.80
Third Closing [Member]
Payments of Stock Issuance Costs						$ 97,099
Stock Units Issued During Period | shares						891,250
Proceeds From Issuance of Stock Units						$ 713,000
Stock Units Description						Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years.
Warrants Exercisable Period						4 years
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 1.40										$ 1.40						$ 1.40
Class of Warrant or Right, Outstanding | shares						89,125										89,125						89,125
Fair Value Adjustment of Warrants						$ 143,389
Warrants Exercisable Price Per Warrants | $ / shares						$ 0.80										$ 0.80						$ 0.80
Convertible Secured Promissory Note [Member]
Debt Conversion, Converted Instrument, Shares Issued | shares										575,234
Debt Conversion, Converted Instrument, Amount										$ 124,523
Fourth Closing [Member]
Payments of Stock Issuance Costs					$ 338,960
Stock Units Issued During Period | shares					3,115,000
Proceeds From Issuance of Stock Units					$ 2,492,000
Stock Units Description					Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years.
Warrants Exercisable Period					4 years
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 1.40
Class of Warrant or Right, Outstanding | shares					311,500
Fair Value Adjustment of Warrants					$ 435,682
Warrants Exercisable Price Per Warrants | $ / shares					$ 0.80
Fifth Closing [Member]
Payments of Stock Issuance Costs				$ 147,566
Stock Units Issued During Period | shares				1,418,750	3,115,000
Proceeds From Issuance of Stock Units				$ 1,135,000	$ 2,492,000
Stock Units Description				Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years.
Warrants Exercisable Period				4 years
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 1.40
Class of Warrant or Right, Outstanding | shares				141,875	311,500
Fair Value Adjustment of Warrants				$ 37,739	$ 435,682
Warrants Exercisable Price Per Warrants | $ / shares				$ 0.80	$ 0.80
Sixth Closing [Member]
Payments of Stock Issuance Costs			$ 211,656
Stock Units Issued During Period | shares			2,035,000
Proceeds From Issuance of Stock Units			$ 1,628,000
Stock Units Description			Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years							Each Unit consisted of one common share of the Company, and a warrant to purchase one common share of the Company at an exercise price of $1.40 per share exercisable for 4 years.
Warrants Exercisable Period			4 years							4 years
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 1.40												$ 1.40
Class of Warrant or Right, Outstanding | shares			203,500												203,500
Fair Value Adjustment of Warrants			$ 74,625
Warrants Exercisable Price Per Warrants | $ / shares			$ 0.80												$ 0.80

STOCK OPTIONS (Details)

STOCK OPTIONS (Details) - Employee Stock Option [Member] - USD ($)	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016
February 17, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	4 years 6 months	5 years
Risk free rate	1.59%	1.59%
Dividend yield	0.00%	0.00%
Forfeiture rate	0.00%	0.00%
Expected volatility	114.00%	114.00%
Grant date fair value fair value	$ 136,613	$ 136,613
July 1, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	3 years 10 months 24 days	4 years 4 months 6 days
Risk free rate	1.59%	1.59%
Dividend yield	0.00%	0.00%
Forfeiture rate	0.00%	0.00%
Expected volatility	114.00%	114.00%
Grant date fair value fair value	$ 1,259,487	$ 1,259,487
June 20, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	6 years 25 days	6 years 3 months 25 days
Risk free rate	1.59%	1.59%
Dividend yield	0.00%	0.00%
Forfeiture rate	0.00%	0.00%
Expected volatility	114.00%	114.00%
Grant date fair value fair value	$ 118,957	$ 118,957
April 11, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	4 years 1 month 20 days	4 years 1 month 20 days
Risk free rate	1.59%	1.59%
Dividend yield	0.00%	0.00%
Forfeiture rate	0.00%	0.00%
Expected volatility	114.00%	114.00%
Grant date fair value fair value	$ 230,930	$ 230,930
November 24, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	6 years 6 months	7 years
Risk free rate	1.59%	1.59%
Dividend yield	0.00%	0.00%
Forfeiture rate	0.00%	0.00%
Expected volatility	114.00%	114.00%
Grant date fair value fair value	$ 694,384	$ 694,384
December 14, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	6 years 6 months	7 years
Risk free rate	1.59%	1.59%
Dividend yield	0.00%	0.00%
Forfeiture rate	0.00%	0.00%
Expected volatility	114.00%	114.00%
Grant date fair value fair value	$ 1,260,437	$ 1,260,437
April 21, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free rate	1.59%
Dividend yield	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value fair value	$ 2,582,890
April 21, 2016 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	9 years 6 months 4 days
April 21, 2016 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	7 months 2 days
April 26, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	6 years 10 months 24 days
Risk free rate	1.59%
Dividend yield	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value fair value	$ 213,750

STOCK OPTIONS (Details 1)

STOCK OPTIONS (Details 1) - $ / shares	1 Months Ended	3 Months Ended			9 Months Ended	12 Months Ended
	Apr. 21, 2016	Jun. 30, 2016	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015	Mar. 31, 2016	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding, Ending Balance (in shares)	3,000,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Options, Outstanding, Beginning Balance (in shares)	6,604,880	6,604,880	6,960,609	3,768,428	4,082,988	4,082,988	1,310,665
Number of Options, Cancelled as a result of Merger (in shares)				(3,768,428)
Number of Options, Re-issued as a result of Merger (in shares)				3,768,428
Number Options, Exercised (in shares)							(1,310,665)
Number of Options, Issued (in shares)		3,250,000		314,560	3,145,000		3,894,252
Number of Options, Cancelled (in shares)		(123,895)	(355,729)		(267,379)		(125,824)
Number of Options, Outstanding, Ending Balance (in shares)		9,730,985	6,604,880	4,082,988	6,960,609	6,604,880	3,768,428
Weighted-Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)	$ 0.57	$ 0.57	$ 0.59	$ 0.22	$ 0.22	$ 0.22	$ 0.19
Weighted-Average Exercise Price, Cancelled as a result of Merger (in dollars per share)				0.22
Weighted-Average Exercise Price, Re-issued as a result of Merger (in dollars per share)				0.22
Weighted-Average Exercise Price, Exercised (in dollars per share)							0.19
Weighted-Average Exercise Price, Issued (in dollars per share)		0.77		0.23	1.05		0.22
Weighted-Average Exercise Price, Cancelled (in dollars per share)		0.45	0.97		0.22		0.17
Weighted-Average Exercise Price, Outstanding, Ending Balance (in dollars per share)		$ 0.64	$ 0.57	$ 0.22	$ 0.59	$ 0.57	$ 0.22

STOCK OPTIONS (Details 2)

STOCK OPTIONS (Details 2) - $ / shares	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	Apr. 21, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options			3,000,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.64	$ 0.57		$ 0.59	$ 0.22	$ 0.22	$ 0.19
Number of Options	9,730,985	6,604,880		6,960,609	4,082,988	3,768,428	1,310,665
Number of Exercisable Options	6,477,238	3,488,476
Stock Option One [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.165	$ 0.165
Number of Options	374,324	437,236
Expiry Date	Apr. 1, 2021	Apr. 1, 2021
Number of Exercisable Options	374,324	291,492
Stock Option Two [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.23	$ 0.23
Number of Options	99,610	99,610
Expiry Date	Jun. 20, 2021	Jun. 20, 2021
Number of Exercisable Options	99,610	67,107
Stock Option Three [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.23	$ 0.23
Number of Options	2,972,592	2,972,592
Expiry Date	Jul. 1, 2021	Jul. 1, 2021
Number of Exercisable Options	2,972,592	2,972,592
Stock Option Four [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.23	$ 0.23
Number of Options	204,460	225,442
Expiry Date	Feb. 17, 2022	Feb. 17, 2022
Number of Exercisable Options	136,314	157,285
Stock Option Five [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1.22	$ 1.22
Number of Options	400,000	400,000
Expiry Date	Nov. 24, 2022	Nov. 24, 2022
Number of Exercisable Options	0	0
Stock Option Six [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1	$ 1
Number of Options	2,430,000	2,470,000
Expiry Date	Dec. 14, 2022	Dec. 14, 2022
Number of Exercisable Options	0	0
Stock Option Seven [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1
Number of Options	250,000
Expiry Date	Apr. 26, 2023
Number of Exercisable Options	0
Stock Option Eight [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.25
Number of Options	906,077
Expiry Date	Jul. 28, 2025
Number of Exercisable Options	906,077
Stock Option Nine [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.25
Number of Options	93,923
Expiry Date	Dec. 30, 2025
Number of Exercisable Options	59,158
Stock Option Ten [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.95
Number of Options	9,486
Expiry Date	Feb. 2, 2017
Number of Exercisable Options	9,486
Stock Option Eleven [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.95
Number of Options	111,937
Expiry Date	Mar. 28, 2023
Number of Exercisable Options	111,937
Stock Option Twelve [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.95
Number of Options	31,620
Expiry Date	Mar. 3, 2024
Number of Exercisable Options	31,620
Stock Option Thirteen [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.95
Number of Options	15,810
Expiry Date	Mar. 14, 2024
Number of Exercisable Options	15,810
Stock Option Fourteen [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.95
Number of Options	82,213
Expiry Date	Sep. 30, 2024
Number of Exercisable Options	82,213
Stock Option Fifteen [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.95
Number of Options	7,431
Expiry Date	Jun. 2, 2025
Number of Exercisable Options	7,431
Stock Option Sixteen [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.95
Number of Options	671,859
Expiry Date	Jul. 29, 2025
Number of Exercisable Options	671,859
Stock Option Seventeen [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.95
Number of Options	69,643
Expiry Date	Dec. 30, 2025
Number of Exercisable Options	8,193
Stock Option Eighteen [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1.05
Number of Options	36,697
Expiry Date	Feb. 2, 2017
Number of Exercisable Options	36,697
Stock Option Nineteen [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1.05
Number of Options	423,642
Expiry Date	Mar. 28, 2023
Number of Exercisable Options	423,642
Stock Option Twenty [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1.05
Number of Options	122,324
Expiry Date	Mar. 3, 2024
Number of Exercisable Options	122,324
Stock Option Twenty one [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1.05
Number of Options	70,548
Expiry Date	Mar. 14, 2024
Number of Exercisable Options	61,162
Stock Option Twenty two [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1.05
Number of Options	318,042
Expiry Date	Sep. 30, 2024
Number of Exercisable Options	318,042
Stock Option Twenty three [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1.05
Number of Options	28,747
Expiry Date	Jun. 2, 2025
Number of Exercisable Options	28,747

STOCK OPTIONS (Details Textual)

STOCK OPTIONS (Details Textual) - USD ($)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Apr. 26, 2016

Apr. 21, 2016

Dec. 14, 2015

Nov. 24, 2015

Feb. 28, 2015

Feb. 26, 2015

Feb. 17, 2015

Jun. 30, 2016

Mar. 31, 2016

Jun. 30, 2015

Dec. 31, 2014

Mar. 31, 2016

Dec. 31, 2015

Mar. 31, 2015

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

3,000,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term

5 years 10 months 20 days

6 years 5 months 19 days

6 years 1 month 28 days

6 years 3 months 7 days

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

5 years 3 months 4 days

6 years 3 months 29 days

5 years 5 months 26 days

6 years 3 months 22 days

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

10,800,000

10,800,000

10,800,000

Exercise Price Range One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

1,000,000

Exercise Price Range Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

1,000,000

Exercise Price Range Three [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

1,000,000

Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated Share-based Compensation Expense

$ 159,818

$ 158,244

$ 1,297,558

$ 112,573

$ 1,464,837

$ 1,467,907

April issuance [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

531,606

Share Based Compensation Arrangement By Share Based Payment Award Options Remeasured Fair value

$ 230,930

June issuance [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

264,230

Share Based Compensation Arrangement By Share Based Payment Award Options Remeasured Fair value

$ 118,957

Allocated Share-based Compensation Expense

$ 118,957

Employees and Consultant [Member] | Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

62,912

125,824

Employees and Consultant [Member] | April issuance [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

657,430

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.165

Employees and Consultant [Member] | April issuance [Member] | Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated Share-based Compensation Expense

$ 3,658

Employees and Consultant [Member] | June issuance [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

264,230

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.23

Employees and Consultant [Member] | June issuance [Member] | Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated Share-based Compensation Expense

$ 176

Management [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

2,972,592

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.23

Share Based Compensation Arrangement By Share Based Payment Award Options Issued Weighted Average Remaining Contractual Term1

7 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

990,864

Fair Value Of Options

$ 1,259,487

Director and Employees and Consultant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

2,495,000

314,560

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.23

Share Based Compensation Arrangement By Share Based Payment Award Options Issued Weighted Average Remaining Contractual Term1

7 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

110,100

40,000

25,000

Allocated Share-based Compensation Expense

$ 7,400

$ 100,308

Fair Value Of Options

$ 1,260,437

$ 136,613

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

3 years

Employees [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

650,000

Fair Value Of Options

$ 694,384

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

3 years

Employees of Bionik Inc [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 1

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

3,895,000

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

250,000

3,000,000

Share-based Compensation Arrangement by Share-based Payment Award Options Vested Weighted Average Grant Date Fair Values

$ 213,750

$ 2,582,890

Employees of Bionik Inc [Member] | Exercise Price Range Three [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 1.05

Employees of Bionik Inc [Member] | Stock Option One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

0.25

Employees of Bionik Inc [Member] | Stock Option Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.95

WARRANTS (Details)

WARRANTS (Details) - $ / shares	3 Months Ended			9 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Number of Warrants, Outstanding and exercisable, Beginning balance	17,900,288	18,049,075	0	10,823,450
Number of Warrants, Issued		18,049,075	10,823,450	7,225,625
Number of Warrants, Exercised	(262,045)	(148,787)
Number of Warrants, Outstanding and exercisable, Ending balance	17,638,243	17,900,288	10,823,450	18,049,075
Weighted-Average Exercise Price, Outstanding and exercisable, Beginning balance	$ 1.35	$ 1.35	$ 0	$ 1.35
Weighted-Average Exercise Price, Issued		1.35	1.35	1.35
Weighted-Average Exercise Price, Exercised	(0.80)	(0.80)
Weighted-Average Exercise Price, Outstanding and exercisable, Ending balance	$ 1.36	$ 1.35	$ 1.35	$ 1.35

WARRANTS (Details 1)

WARRANTS (Details 1) - $ / shares	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	Feb. 29, 2016	Dec. 31, 2015	Mar. 31, 2015
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.80
Class of Warrant or Right, Number of Warrants	17,638,243	17,900,288		18,049,075	10,823,450
Warrant One [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.40	$ 1.40
Class of Warrant or Right, Number of Warrants	7,735,750	7,735,750		7,735,750
Class Of Warrant Or Right Expiry Date	Feb. 26, 2019	Feb. 26, 2019
Warrant Two [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.80
Class of Warrant or Right, Number of Warrants		773,575		773,575
Class Of Warrant Or Right Expiry Date		Feb. 26, 2019
Warrant Three [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.40	$ 1.40
Class of Warrant or Right, Number of Warrants	1,212,500	1,212,500		1,212,500
Class Of Warrant Or Right Expiry Date	Mar. 27, 2019	Mar. 27, 2019
Warrant Four [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.80
Class of Warrant or Right, Number of Warrants		121,250		121,250
Class Of Warrant Or Right Expiry Date		Feb. 26, 2019
Warrant Five [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.40	$ 1.40
Class of Warrant or Right, Number of Warrants	891,250	891,250		891,250
Class Of Warrant Or Right Expiry Date	Mar. 31, 2019	Mar. 31, 2019
Warrant Six [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.80
Class of Warrant or Right, Number of Warrants		89,125		89,125
Class Of Warrant Or Right Expiry Date		Feb. 26, 2019
Warrant Seven [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.40	$ 1.40
Class of Warrant or Right, Number of Warrants	3,115,000	3,115,000		3,115,000
Class Of Warrant Or Right Expiry Date	Apr. 21, 2019	Apr. 21, 2019
Warrant Eight [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.80
Class of Warrant or Right, Number of Warrants		311,500		311,500
Class Of Warrant Or Right Expiry Date		Feb. 26, 2019
Warrant Nine [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.40	$ 1.40
Class of Warrant or Right, Number of Warrants	1,418,750	1,418,750		1,418,750
Class Of Warrant Or Right Expiry Date	May 27, 2019	May 27, 2019
Warrant Ten [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.80
Class of Warrant or Right, Number of Warrants		141,875		141,875
Class Of Warrant Or Right Expiry Date		Feb. 26, 2019
Warrant Eleven [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.40	$ 1.40
Class of Warrant or Right, Number of Warrants	2,035,000	2,035,000		2,035,000
Class Of Warrant Or Right Expiry Date	Jun. 30, 2019	Jun. 30, 2019
Warrant Twelve [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.80
Class of Warrant or Right, Number of Warrants		54,713		203,500
Class Of Warrant Or Right Expiry Date		Feb. 26, 2019
Warrant Thirteen [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.80
Class of Warrant or Right, Number of Warrants	1,229,993
Class Of Warrant Or Right Expiry Date	Feb. 26, 2019

WARRANTS (Details 2)

WARRANTS (Details 2) - USD ($)	1 Months Ended		3 Months Ended				9 Months Ended			12 Months Ended
	Mar. 01, 2016	Feb. 29, 2016	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2015	Mar. 31, 2015	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015
Class of Warrant or Right, Outstanding			17,638,243	17,900,288		10,823,450	17,900,288	18,049,075		17,900,288	18,049,075	10,823,450
Derivative Liability, Fair Value, Gross Liability						$ 8,382,648		$ 6,067,869			$ 6,067,869	$ 8,382,648
Fair value of warrants exercised			$ (43,562)	$ (60,966)
Change in fair value of warrant derivative liability			391,059	(870,913)	$ (917,749)	6,387,473	$ (7,419,643)	(7,419,643)	$ 0	$ (7,742,555)	(484,124)	6,387,473
Derivative Liability			$ 5,527,049	$ 5,135,990		$ 8,382,648	$ 5,135,990	$ 6,067,869	$ 0	$ 5,135,990	$ 6,067,869	$ 8,382,648
Number Of Warrants Exercised	148,787	148,787	(262,045)	(148,787)
Warrants Issued In February 26, 2015 Financing [Member]
Class of Warrant or Right, Outstanding						8,509,325						8,509,325
Derivative Liability, Fair Value, Gross Liability						$ 550,374						$ 550,374
Warrants Issued In March 27, 2015 Financing [Member]
Class of Warrant or Right, Outstanding						1,333,750						1,333,750
Derivative Liability, Fair Value, Gross Liability						$ 1,036,325						$ 1,036,325
Warrants Issued In March 31, 2015 Financing [Member]
Class of Warrant or Right, Outstanding						980,375						980,375
Derivative Liability, Fair Value, Gross Liability						$ 759,290						$ 759,290
Warrants Issued In April 21, 2015 Financing [Member]
Class of Warrant or Right, Outstanding					3,426,500			3,426,500			3,426,500
Derivative Liability, Fair Value, Gross Liability					$ 2,588,722			$ 2,588,722			$ 2,588,722
Warrants Issued In May 27, 2015 Financing [Member]
Class of Warrant or Right, Outstanding					1,560,625			1,560,625			1,560,625
Derivative Liability, Fair Value, Gross Liability					$ 1,025,173			$ 1,025,173			$ 1,025,173
Warrants Issued In June 30, 2015 Financing [Member]
Class of Warrant or Right, Outstanding					2,238,500			2,238,500			2,238,500
Derivative Liability, Fair Value, Gross Liability					$ 1,490,969			$ 1,490,969			$ 1,490,969

WARRANTS (Details 3)

WARRANTS (Details 3) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015
Number of Warrants	17,638,243	17,900,288	17,900,288	18,049,075	10,823,450
Warrant One [Member]
Number of Warrants	7,735,750	7,735,750	7,735,750	7,735,750
Expected life in years			4 years	4 years
Exercise Price				$ 1.4
Risk free rate			0.44%	0.44%
Dividend rate			0.00%	0.00%
Expected volatility			51.83%	51.83%
Grant date fair value				$ 464,784
Warrant Two [Member]
Number of Warrants		773,575	773,575	773,575
Expected life in years			4 years	4 years
Exercise Price				$ 0.8
Risk free rate			0.44%	0.44%
Dividend rate			0.00%	0.00%
Expected volatility			51.83%	51.83%
Grant date fair value				$ 85,590
Warrant Three [Member]
Number of Warrants	1,212,500	1,212,500	1,212,500	1,212,500
Expected life in years			3 years 11 months 1 day	3 years 11 months 1 day
Exercise Price				$ 1.4
Risk free rate			0.43%	0.43%
Dividend rate			0.00%	0.00%
Expected volatility			52.37%	52.37%
Grant date fair value				$ 950,913
Warrant Four [Member]
Number of Warrants		121,250	121,250	121,250
Expected life in years			3 years 11 months 1 day	3 years 11 months 1 day
Exercise Price				$ 0.8
Risk free rate			0.43%	0.43%
Dividend rate			0.00%	0.00%
Expected volatility			52.37%	52.37%
Grant date fair value				$ 85,412
Warrant Five [Member]
Number of Warrants	891,250	891,250	891,250	891,250
Expected life in years			3 years 10 months 28 days	3 years 10 months 28 days
Exercise Price				$ 1.4
Risk free rate			0.41%	0.41%
Dividend rate			0.00%	0.00%
Expected volatility			52.45%	52.45%
Grant date fair value				$ 696,582
Warrant Six [Member]
Number of Warrants		89,125	89,125	89,125
Expected life in years			3 years 10 months 28 days	3 years 10 months 28 days
Exercise Price				$ 0.8
Risk free rate			0.41%	0.41%
Dividend rate			0.00%	0.00%
Expected volatility			52.45%	52.45%
Grant date fair value				$ 62,708
Warrant Seven [Member]
Number of Warrants	3,115,000	3,115,000	3,115,000	3,115,000
Expected life in years			3 years 10 months 6 days	3 years 10 months 6 days
Exercise Price				$ 1.4
Risk free rate			0.68%	0.68%
Dividend rate			0.00%	0.00%
Expected volatility			51.54%	51.54%
Grant date fair value				$ 2,371,956
Warrant Eight [Member]
Number of Warrants		311,500	311,500	311,500
Expected life in years			3 years 10 months 6 days	3 years 10 months 6 days
Exercise Price				$ 0.8
Risk free rate			0.68%	0.68%
Dividend rate			0.00%	0.00%
Expected volatility			51.54%	51.54%
Grant date fair value				$ 216,766
Warrant Nine [Member]
Number of Warrants	1,418,750	1,418,750	1,418,750	1,418,750
Expected life in years			3 years 9 months 4 days	3 years 9 months 4 days
Exercise Price				$ 1.4
Risk free rate			0.46%	0.46%
Dividend rate			0.00%	0.00%
Expected volatility			51.74%	51.74%
Grant date fair value				$ 933,065
Warrant Ten [Member]
Number of Warrants		141,875	141,875	141,875
Expected life in years			3 years 9 months 4 days	3 years 9 months 4 days
Exercise Price				$ 0.8
Risk free rate			0.46%	0.46%
Dividend rate			0.00%	0.00%
Expected volatility			51.74%	51.74%
Grant date fair value				$ 92,108
Warrant Eleven [Member]
Number of Warrants	2,035,000	2,035,000	2,035,000	2,035,000
Expected life in years			3 years 7 months 28 days	3 years 7 months 28 days
Exercise Price				$ 1.4
Risk free rate			0.37%	0.37%
Dividend rate			0.00%	0.00%
Expected volatility			52.94%	52.94%
Grant date fair value				$ 1,356,512
Warrant Twelve [Member]
Number of Warrants		54,713	54,713	203,500
Expected life in years			3 years 7 months 28 days	3 years 7 months 28 days
Exercise Price				$ 0.8
Risk free rate			0.37%	0.37%
Dividend rate			0.00%	0.00%
Expected volatility			52.94%	52.94%
Grant date fair value				$ 134,457
Classes of Warrants 1 [Member]
Number of Warrants	16,408,250	16,408,250	16,408,250	16,408,250	9,839,500
Expected life in years	2 years 7 months 28 days	2 years 10 months 28 days		3 years 1 month 28 days	3 years 10 months 28 days
Exercise Price	$ 1.4	$ 1.4	$ 1.4	$ 1.4	$ 1.4
Risk free rate	0.26%	0.21%		0.65%	0.41%
Dividend rate	0.00%	0.00%		0.00%	0.00%
Expected volatility	70.77%	62.96%		53.58%	52.45%
Grant date fair value	$ 5,003,830	$ 4,585,539	$ 4,585,539	$ 5,315,536	$ 7,690,340
Classes Of Warrants 2 [Member]
Number of Warrants	1,229,993	1,492,038	1,492,038	1,640,825	983,950
Expected life in years	2 years 7 months 28 days	2 years 10 months 28 days		3 years 1 month 28 days	3 years 10 months 28 days
Exercise Price	$ 0.8	$ 0.8	$ 0.8	$ 0.8	$ 0.8
Risk free rate	0.26%	0.21%		0.65%	0.41%
Dividend rate	0.00%	0.00%		0.00%	0.00%
Expected volatility	70.77%	62.96%		53.58%	52.45%
Grant date fair value	$ 523,219	$ 550,451	$ 550,451	$ 752,333	$ 692,308

WARRANTS (Details Textual)

WARRANTS (Details Textual) - USD ($)	1 Months Ended		3 Months Ended				9 Months Ended			12 Months Ended
	Mar. 01, 2016	Feb. 29, 2016	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2015	Mar. 31, 2015	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.80
Fair Value Adjustment of Warrants			$ 391,059	$ (870,913)	$ (917,749)	$ 6,387,473	$ (7,419,643)	$ (7,419,643)	$ 0	$ (7,742,555)	$ (484,124)	$ 6,387,473
Warrant Redemption Terms			The Company has the option to redeem the warrants for $0.001 per warrant if the daily volume weighted-average price of the common shares is 200% or more of the exercise price for twenty consecutive trading days provided there is an effective registration statement covering the common shares available throughout the thirty day period after the redemption date. The warrant holders then have thirty days to exercise the warrants or receive the redemption amount.	The Company has the option to redeem the warrants for $0.001 per warrant if the daily volume weighted-average price of the common shares is 200% or more of the exercise price for twenty consecutive trading days provided there is an effective registration statement covering the common shares available throughout the thirty day period after the redemption date. The warrant holders then have thirty days to exercise the warrants or receive the redemption amount.
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumption, Holding Cost Percentage				2.25%
Daily Volume Weighted Average Share Price Minimum Threshold Percentage				200.00%
Stock Issued During Period, Shares, Upon Cashless Exercise Of Warrants	45,508	45,508	51,249
Number Of Warrants Exercised	148,787	148,787	(262,045)	(148,787)
Warrant [Member]
Class of Warrant or Right [Line Items]
Derivative, Gain (Loss) on Derivative, Net, Total				$ 548,046
Increase (Decrease) in Derivative Liabilities				8,290,601							1,382,984
Fair Value Adjustment of Warrants				$ 870,913						$ 7,742,555	$ 484,124
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms				2 years 9 months 7 days					3 years 1 month 28 days			3 years 11 months 5 days	0 years
Investor [Member]
Class of Warrant or Right [Line Items]
Repayments of Debt									$ 180,940
Debt Conversion, Converted Instrument, Warrants or Options Issued									349,522
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 0.23				$ 0.23
Investor [Member] | Accrued Liabilities [Member]
Class of Warrant or Right [Line Items]
Repayments of Debt									$ 12,138

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2014	Mar. 31, 2016	Dec. 31, 2015
Components of net loss before income taxes consists of the following:
U.S.	$ 183,461	$ 0	$ 4,706,413	$ (2,372,510)
Canada	(1,187,553)	(2,464,747)	(3,670,265)	(3,221,396)
Net loss for the period before recovery of income taxes	$ (1,004,092)	$ (2,464,747)	$ 1,036,148	$ (5,593,906)
Statutory rate	35.00%	26.50%	35.00%	35.00%
Expected income tax (recovery) expense	$ (351,432)	$ (653,158)	$ 362,652	$ (1,957,867)
Tax rate changes and other basis adjustments	(162,267)	(29,109)	195,108	364,651
Change in fair value of derivative liability	(304,835)		(2,709,894)	(169,443)
Stock-based compensation	55,350	0	512,693	587,381
Non-deductible expenses	(99,642)	193,305	(12,073)	227,068
Change in valuation allowance	862,826	488,962	1,651,514	948,210
Recovery of income taxes	$ 0	$ 0	$ 0	$ 0

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Property and equipment	$ 52,331	$ 47,495	$ 34,556	$ 36,940
Share issue costs	3,586	3,877	5,838	162,350
SR&ED pool	400,557	340,585	103,799	7,137
Other	215,202	39,947	32,447	18,621
Non-capital losses - Canada	1,587,439	1,149,389	977,178	812,522
Net operating losses - U.S.	589,491	404,487	43,274	0
Valuation allowance	(2,848,606)	(1,985,780)	(1,197,092)	(1,037,570)
Deferred Tax Liabilities, Net, Total	$ 0	$ 0	$ 0	$ 0

INCOME TAXES (Details 2)

INCOME TAXES (Details 2)	12 Months Ended
	Mar. 31, 2016
Domestic Tax Authority [Member] | United States - Federal [Member]
Income Tax Examination Open Tax Years	2013 present
Domestic Tax Authority [Member] | United States - State [Member]
Income Tax Examination Open Tax Years	2013 present
Foreign Tax Authority [Member] | Canada - Federal[Member]
Income Tax Examination Open Tax Years	2012 - present
Foreign Tax Authority [Member] | Canada - Provincial[Member]
Income Tax Examination Open Tax Years	2012 - present

INCOME TAXES (Details Textual)

INCOME TAXES (Details Textual) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2014	Mar. 31, 2016	Dec. 31, 2015
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	35.00%	26.50%	35.00%	35.00%
Tax Credit Carryforward, Amount	$ 1,684,261		$ 1,684,261
Canada [Member]
Tax Credit Carryforward, Amount	$ 5,990,000		$ 5,990,000

LICENSING AGREEMENTS (Details T

LICENSING AGREEMENTS (Details Textual)	3 Months Ended
	Jun. 30, 2016USD ($)
Licensing Agreement One [Member]
Sublicense Revenue Percentage	50.00%
Royalty Expense	$ 0
Accrued Royalties, Current	$ 31,388
Licensing Agreement One [Member] | Domestic Product Sales [Member]
Royalty Payable Percentage	3.00%
Licensing Agreement One [Member] | International product sales [Member]
Royalty Payable Percentage	1.50%
Licensing Agreement Two [Member]
Royalty Payable Percentage	1.00%
Sublicense Revenue Percentage	50.00%

RISK MANAGEMENT (Details Textua

RISK MANAGEMENT (Details Textual) - CAD	Jun. 30, 2016	Mar. 31, 2016
Canada [Member] | Maximum [Member]
Concentration Risk [Line Items]
Cash, FDIC Insured Amount	CAD 100,000	CAD 100,000

SUBSEQUENT EVENTS (Details Text

SUBSEQUENT EVENTS (Details Textual) - USD ($)	Aug. 08, 2016	Jul. 31, 2016	Apr. 30, 2016	Apr. 21, 2016	Mar. 01, 2016	Feb. 29, 2016	Jun. 30, 2016	Mar. 31, 2016	Mar. 31, 2016	Dec. 31, 2015
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.80
Stock Issued During Period, Value, Issued for Services							$ 59,500	$ 70,800	$ 169,700	$ 98,900
Stock Issued During Period, Shares, Upon Cashless Exercise Of Warrants					45,508	45,508	51,249
Number Of Warrants Exercised					148,787	148,787	(262,045)	(148,787)
IMT Equity Incentive Plan [Member]
Subsequent Event [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance					3,000,000
Reserved Options Price 0.25 [Member]
Subsequent Event [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance					1,000,000
Reserved Options Price					$ 0.25
Reserved Options Price 0.95 [Member]
Subsequent Event [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance					1,000,000
Reserved Options Price					$ 0.95
Reserved Options Price 1.05 [Member]
Subsequent Event [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance					1,000,000
Reserved Options Price					$ 1.05
Subsequent Event [Member]
Subsequent Event [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance				23,650,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	750,000
Proceeds from Income Tax Refunds		$ 403,889
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 1
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Subsequent Event [Member] | Interactive Motion Technologies Inc [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.80
Stock Issued During Period, Shares, Issued for Services			70,000
Stock Issued During Period, Value, Issued for Services			$ 70,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				3,895,000
Stock Issued During Period, Shares, Upon Cashless Exercise Of Warrants			51,249
Number Of Warrants Exercised			262,045
Business Acquisition, Percentage of Voting Interests Acquired				100.00%

(LOSS) PER SHARE (Details)

(LOSS) PER SHARE (Details) - USD ($)	3 Months Ended				9 Months Ended			12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2015	Mar. 31, 2015	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015
Numerator
Net income								$ 1,036,148
Change in fair value of warrant derivative liability	$ 391,059	$ (870,913)	$ (917,749)	$ 6,387,473	$ (7,419,643)	$ (7,419,643)	$ 0	(7,742,555)	$ (484,124)	$ 6,387,473
Net (loss) used in computation of diluted EPS								$ (6,706,407)
Denominator
Basic weighted average number of shares outstanding		72,455,753					48,225,034	71,554,822	67,210,266	50,226,548
Warrants								8,429,435
Diluted weighted average number of shares outstanding		72,455,753					48,225,034	79,984,257	67,210,266	50,226,548
Diluted loss per share		$ (0.01)					$ (0.05)	$ (0.08)	$ (0.08)	$ (0.20)

TRANSITION PERIOD COMPARATIVE73

TRANSITION PERIOD COMPARATIVE DATA (Details) - USD ($)	3 Months Ended				9 Months Ended			12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2015	Mar. 31, 2015	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015
Operating Data:
Research and development	$ 417,790	$ 343,742	$ 609,823	$ 435,671			$ 1,101,820	$ 1,397,554	$ 1,489,483	$ 1,537,491
Professional and consulting fees				261,350
General and administrative	1,303,614	1,438,553	510,229	167,747			1,192,244	3,676,125	2,666,669	1,621,341
Depreciation	10,163	14,387	17,002	10,412			34,036	63,454	59,479	44,448
Share-based compensation expense	219,248	158,244	1,297,558	371,637			112,573	1,495,837	1,709,230	484,210
Operating Expenses, Total	2,033,013	1,954,926	2,434,612	1,246,817			2,440,673	6,632,970	5,924,861	3,687,490
Other expenses (income)
Interest expense	15,234	0	9,963	179			6,212	2,839	3,018	6,391
Other income				(323)
Change in fair value of warrant derivative liability	391,059	(870,913)	(917,749)	6,387,473	$ (7,419,643)	$ (7,419,643)	0	(7,742,555)	(484,124)	6,387,473
Total other expense (income)				6,387,329
Net loss for the period	(2,322,772)	(1,004,092)	(1,501,618)	(7,634,146)	$ 2,537,766	2,040,240	(2,464,747)	1,036,148	(5,593,906)	(10,098,893)
Foreign exchange translation adjustment for the period		0		24,799		$ 0	(24,390)	0	24,799	409
Net loss and comprehensive loss for the period	$ (2,322,772)	(1,004,092)	$ (1,501,618)	$ (7,609,347)			(2,489,137)	1,036,148	(5,569,107)	(10,098,484)
Loss per share - basic and diluted	$ (0.03)		$ (0.02)	$ (0.14)
Weighted Average Number of Shares Outstanding, Basic and Diluted	82,050,549		68,765,736	52,726,746
Cash flow Data:
Net cash used in operating activities	$ (2,898,439)	(1,038,390)	$ (1,422,793)	$ (825,483)			(1,639,478)	(4,747,836)	(4,590,387)	(2,464,961)
Net cash used in investing activities	0	(196,935)	(180,917)	(38,820)			(109,316)	(547,924)	(380,195)	(148,136)
Net cash provided by financing activities	266,635	0	4,552,409	6,788,988			1,988,678	4,552,409	11,341,397	8,777,666
Effects of foreign currency exchange rate changes	0	0	4,409	(9,510)			(33,433)	0	36,334	(42,943)
Net increase in cash and cash equivalents for the period	$ (2,631,804)	$ (1,235,325)	$ 2,953,108	$ 5,915,175			$ 206,451	$ (743,351)	$ 6,407,149	$ 6,121,626

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details)	1 Months Ended
	Apr. 21, 2016USD ($)
Consideration Paid:
Fair value of 23,650,000 common shares	$ 23,177,000	[1]
Fair value of vested stock options	2,582,890	[2]
Consideration Paid Total	25,759,890
Allocation of purchase price:
Allocation of purchase price Total	(2,129,089)
Subsequent Event [Member]
Allocation of purchase price:
Net assets acquired	(2,129,089)
Intangible assets and goodwill	26,879,318
Allocation of purchase price Total	24,750,229
Subsequent Event [Member] | Interactive Motion Technologies Inc [Member]
Consideration Paid:
Fair value of 23,650,000 common shares	23,177,000
Fair value of vested stock options	1,573,229
Consideration Paid Total	$ 24,750,229
[1]	The fair value of common shares is based on $0.98 the closing market price of the Company’s shares on April 21, 2016.
[2]	The fair value of the vested stock options was determined using the Black Scholes option pricing model with the following key assumptions: a risk free rate of 1.59%, dividend and forfeiture rates of 0% and expected volatility of 114% which is consistent with the Company’s assumptions (Note 10)

SUBSEQUENT EVENTS (Details) (pa

SUBSEQUENT EVENTS (Details) (parenthetical) - shares	1 Months Ended	3 Months Ended
	Apr. 21, 2016	Jun. 30, 2016
Business Acquisition [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		23,650,000
Interactive Motion Technologies Inc [Member]
Business Acquisition [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	23,650,000
Subsequent Event [Member] | Interactive Motion Technologies Inc [Member]
Business Acquisition [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	23,650,000

SUBSEQUENT EVENTS (Details 1)

SUBSEQUENT EVENTS (Details 1) - USD ($)	3 Months Ended				9 Months Ended			12 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2015	Mar. 31, 2015	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015
Business Acquisition [Line Items]
Sales								$ 1,919,779
Net loss for the period	$ (2,322,772)	$ (1,004,092)	$ (1,501,618)	$ (7,634,146)	$ 2,537,766	$ 2,040,240	$ (2,464,747)	$ 1,036,148	$ (5,593,906)	$ (10,098,893)